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 Significant changes in dietary habits have led to a rampant increase in metabolic 
disorders. Non-alcoholic fatty liver disease (NAFLD) is one such disorder characterized 
by the excess buildup of fat in hepatocytes of people who drink little or no alcohol. If not 
managed, NAFL (simple steatosis) progress into nonalcoholic steatohepatitis (NASH) and 
further deteriorate to cirrhosis leading to severe illness or even death. Drug disposition 
proteins (enzymes and transporters) in liver control the systemic exposure of drugs and 
xenobiotics in human and drive the efficacy as well as adverse events in the body. 
Therefore, it is critical to address the effect of NAFLD on the abundance of these proteins. 
A variation would result in an altered pharmacokinetic and/or pharmacodynamic profile of 
substrate drugs in patients with NAFLD. Most studies were performed in preclinical 
species (rat, mice) and only a few reports are available in human. The primary objective of 
this doctoral project was to investigate the effect of NALFD on the abundance of hepatic 
drug disposition proteins (DDP) in a human liver-bank. The levels of proteins were 
determined using an LC-MS/MS based label-free, global proteomics method. In addition, 
CYP3A4 enzyme kinetics parameters were determined using midazolam as a probe 
substrate. Considerable changes in the protein expression and activity of CYP3A4 and 
CYP1A2 were found in NAFL and NASH. Only marginal alterations were observed for 
other cytochrome P450 enzymes in this study. Levels of uridine 5'-diphospho-
glucuronosyltransferases (UGT) and sulfotransferases (SULT) in NAFLD were mostly 
unaltered. Dysregulation of mitochondrial proteins involved in lipid metabolism 
(ACADSB, ACSM3/5, CPS1) was also observed. A significant downregulation of 
CYP3A4 protein and activity but not mRNA in NAFLD was observed suggesting that post-
 
 
transcriptional changes may play a more significant role in the observed phenotypic 
perturbations for the isoform. Overall, enzyme kinetics and quantitative protein abundance 
data from this project will be important in the development of physiologically based 
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Significant lifestyle and diet changes in last few decades have led to a rampant increase in 
metabolic diseases in human. Nonalcoholic fatty liver disease (NAFLD) is characterized 
by the excessive buildup of fats in the liver. The disease can range from simple steatosis 
(fat accumulation) to nonalcoholic steatohepatitis (NASH) which represents a severe form 
of NAFLD and is accompanied with inflammation, fibrosis and hepatocyte damage in 
addition to significant steatosis. Hepatic proteins involved in metabolism (enzymes) and 
uptake/efflux (transporters) of xenobiotics are collectively known as drug disposition 
proteins (DDPs). While the expression of DDPs is well studied in healthy volunteers, our 
understanding of the alterations of these proteins in NAFLD is limited. Much of the 
existing knowledge on the subject is derived from pre-clinical species, and clinical 
translation of these findings is poor. The effect of NAFLD on these proteins in human is 
debatable and currently lacks a consensus among different reports. Global label-free, mass-
spectrometry-based quantitative proteomics is a promising tool to study the changes 
associated with NAFLD without the need for protein-specific targeted quantification. 
Protein expression is important in vitro physiological parameter controlling the 
pharmacokinetics. The last decade has also seen a rise in the use of physiologically based 
pharmacokinetic (PBPK) modeling for prediction of drug pharmacokinetics in special 
populations. Here, we present a review of current literature on the alterations in human 
hepatic DDPs in NAFLD.  
 





Substantial changes in the dietary habits of our generation are fueling an epidemic 
of various metabolic disorders. Nonalcoholic fatty acid liver disease (NAFLD) is one such 
metabolic syndrome which is rising at an alarming rate (Ahmed 2015; Mikolasevic et al. 
2016). The prevalence of NAFLD is higher in patients with diabetes, obesity, hyperlipemia, 
hypertension and hypertriglyceridemia (Lonardo et al. 2016; Younossi, Koenig, et al. 
2016). NAFLD is characterized by the presence of greater than 5% of hepatic fat in people 
without significant alcohol intake (<20 g per day for women, <30 g per day for men) 
(Chalasani et al. 2012; Leoni et al. 2018). Fat-accumulation in hepatocytes is triggered by 
various mechanisms which include the increased hepatic uptake of circulating fatty acids, 
increased hepatic de novo fatty acid synthesis, decreased hepatic beta-oxidation and 
decreased hepatic lipid export (Geisler and Renquist 2017). The disease is characterized 
by the accumulation of free fatty acids and triglycerides in the hepatocytes, and severity 
ranges from benign steatosis to nonalcoholic steatohepatitis (figure 1) (McCullough 2006). 
NASH, characterized by significant lobular inflammation, hepatic fibrosis, and hepatocyte 
necrosis, can progress to life-threatening liver cirrhosis and hepatocellular carcinoma 
(HCC) (Farrell and Larter 2006).  
Pathogenesis, epidemiology and risk factors 
The current “multiple hit” theory for the pathogenesis of NAFLD proposes first hit 
as the accumulation of lipid droplets (triglycerides) in >5% of liver hepatocytes (Takaki et 
al. 2014). A successive second hit characterized by excessive free radical and pro-
inflammatory cytokine formation leading to inflammation, necrosis and consequently, 




in the past decade for diagnostic evaluation of different stages of NAFLD (Brunt E. M. et 
al. 1999; Kleiner et al. 2005; Bedossa et al. 2012). Pathologists commonly differentiate 
different stages of NAFLD using semi-quantitative evaluation based on steatosis, lobular 
inflammation, hepatocellular ballooning, and/or fibrosis (Brunt E. M. 2016). Liver biopsy 
is the gold standard for the diagnosis of NAFLD but ethical, and feasibility constraints limit 
the direct assessment of its prevalence. The global prevalence of NAFLD diagnosed by 
imaging was estimated to be 25.2%, and it was >30% in the Middle East and South 
America (Chalasani et al. 2018). The lowest prevalence of NAFLD was reported from 
Africa (13.5%). The prevalence of NAFLD diagnosed with ultrasonography was 24.13%. 
The overall prevalence of nonalcoholic steatohepatitis (NASH) in general populations is 
estimated to be between 1.5-6.5% (Chalasani et al. 2018). In the USA, NAFLD is also 
associated with significant economic (~$103 billion) and clinical burden (~64 million 
people projected to have NAFLD) (Younossi, Blissett, et al. 2016).  Ethnic differences 
exist in the prevalence of NALFD and Hispanics are more susceptible to the disease as 
compared to Caucasians and Afro-Americans (Kalia and Gaglio 2016). The disease was 
initially thought to be present only in obese adults; however recent studies have shown its 
prevalence in people with normal BMI as well as children (Margariti et al. 2012; Anderson 
et al. 2015; Bush et al. 2017). Certain genetic factors are also responsible for predisposition 
of carriers to NAFLD. PNLA3 (Patatin-like phospholipase domain-containing protein 3) 
is a multifunctional enzyme involved in the hydrolysis of triacylglycerol (TAG) in the liver, 
and rs738409 variant is the strongest genetic risk factor for NAFLD (Romeo et al. 2008). 
Recent genome-wide association studies (GWAS) have identified increased NAFLD 




2), GCKR (rs780094, Glucokinase regulator), NCAN (rs2228603, Neurocan), LYPLAL1 
(rs12137855, Lysophospholipase-like 1) (Sookoian and Pirola 2017; Sliz et al. 2018). The 
association of rs641738 variant of MBOAT7-TMC4 locus (membrane bound O-
acyltransferase domain-containing 7, transmembrane channel-like 4) is controversial and 
inconclusive (Mancina et al. 2016; Sookoian et al. 2018).   
Physical findings show that patients with NAFLD often have obesity and 
hepatomegaly (enlarged liver) due to fat infiltration of the liver. NAFLD patients show 
mild or moderate elevations in the aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), although normal aminotransferase levels do not exclude NAFLD. 
When elevated, the AST and ALT are typically 2 to 5 times the upper limit of normal with 
an AST to ALT ratio of less than one (>1.5 for alcoholic liver disease) (Sattar et al. 2014). 
Alkaline phosphatase may also be elevated 2-3 times the upper limit of normal and patients 
may have an elevated serum ferritin concentration or transferrin saturation. Decreased 
hepatic attenuation on computed tomography (CT) and an increased fat signal on magnetic 
resonance imaging (MRI) are generally evident in radiographic findings (Decarie et al. 
2011). 
Classification systems for NAFLD 
NAFLD is a complex disease and differentiating definite NASH from NAFL can 
be equally complicated for basic researchers as well as for pathologists. The gray zone of 
distinction between NAFL and NASH is precarious, and diagnosis often varies 
dramatically among pathologists due to the heterogenous histopathologic spectrum of 




use of these classifications has led to misuse of scoring systems (Kleiner et al. 2005; 
Angulo Paul 2011; Brunt Elizabeth M. et al. 2011). The categorical nature of the 
histopathological scoring system adds to the discrepancies in the diagnosis of the type of 
NAFLD. Since the categories are not well-defined, it eventually leads to varying 
interpretations and conclusions from researchers and pathologists (Brunt E. M. 2016). 
Additive nature of recent scoring systems (NAS or SAF) deconvolutes the contribution of 
each histologic legion. Interestingly, NAS scoring system was not designed to be used as 
a diagnostic tool for determination of NASH versus NAFL (Kleiner et al. 2005; Brunt 
Elizabeth M. et al. 2011). It was intended to evaluate the changes in histological lesions 
(steatosis, inflammation, hepatocyte ballooning, fibrosis) that can occur over time (Angulo 
P. 2011).  Fatty liver inhibition of progression (FLIP) algorithm was proposed to improve 
the consistency in the diagnosis of NASH in adults and takes into account fibrosis along 
with steatosis and activity score (inflammation, ballooning) (Younossi et al. 2011). The 
use of different classification systems may, therefore, contribute to significant variability 
seen in the literature on the subject. Surgical hepatitis and potential differences between 
the biopsy site (right or left lobe) also confound the diagnosis of histologic lesions and 
subsequently the proper classification of disease (Brunt E. M. 2016).  
Treatment strategies to manage NAFLD 
Hepatic pathological conditions have been known to impact the abundance of DMEs and 
transporters in the liver, leading to altered drug profiles and often to side-effects (Gandhi 
et al. 2012). Despite the widespread prevalence of NAFLD/NASH, currently, there are no 
pharmacological therapies available for its treatment and involves the management of 




al. 2016; Sumida et al. 2016). Weight loss is usually the first and most common 
intervention recommended for any metabolic syndrome (Marchesini et al. 2016). Similarly, 
lifestyle modifications through exercise and dietary restriction are considered vital in the 
management of NAFLD (Vilar-Gomez et al. 2015). Patients with the disease are advised 
to avoid intake of positive calorie foods like soda and sweetened drink which are rich in 
simple carbohydrates which are readily absorbed (Zivkovic et al. 2007). Patients are also 
asked/recommended to avoid diets rich in cholesterol, fructose and other saturated fats 
which are often linked with progression of NAFLD (Musso et al. 2009; Abdelmalek et al. 
2010). 
Interestingly, consumption of fructose-sweetened and non-glucose sweetened beverages 
has been associated with elevated insulin resistance and an increase in visceral adiposity 
and lipids in overweight and obese humans (Stanhope et al. 2009). Ryan et al. found that 
the Mediterranean diet improved insulin sensitivity and reduced hepatic steatosis in 
NAFLD patients with insulin-resistance (Ryan et al. 2013). A considerable effort is 
currently underway in the development of therapeutic agents for the treatment of NAFLD, 
and multiple molecular pathways are now being targeted for drug development (Perazzo 
and Dufour 2017). Pioglitazone, vitamin E and, GLP-1 and SGLT2 inhibitors have shown 
some efficacy in NASH. New therapies in development target one or more of the following 
pathways; a) hepatic fat accumulation and insulin resistance, b) oxidative stress, 
inflammation and apoptosis, and c) hepatic fibrosis (Sumida and Yoneda 2018). An 
overview of some of the therapeutic agents in clinical development is given in table 1. 
Leoni et al. recently published a review analyzing the current guidelines in the diagnosis 




Drug metabolism enzymes and NAFLD 
Human liver, facilitated by several drug metabolizing enzymes (DMEs), is the 
primary organ responsible for the elimination of xenobiotics and endogenous compounds. 
DMEs are responsible for the metabolism of diverse chemicals which include xenobiotics 
like drugs, pesticides and endogenous substrates like steroids and bile acids (Zanger and 
Schwab 2013). DMEs are broadly classified into phase I enzymes which are mostly 
oxidative, reductive or hydrolytic; and phase II enzymes which are conjugative. Major 
proteins involved in oxidative biotransformation belongs to cytochrome P450 (CYP450s), 
flavin-monooxygenases (FMOs), monoamine oxidases (MAOs), alcohol and aldehyde 
dehydrogenases, and aldehyde and xanthine oxidase (Appendix: Drug Metabolizing 
Enzymes and Biotransformation Reactions  2012). Aldo-keto reductases (AKRs), azo- and 
nitro-reductases constitute reductive enzymes involved in metabolism whereas epoxide 
hydrolases, esterases, and peptidases are responsible for the bulk of hydrolysis reactions in 
the liver (Appendix: Drug Metabolizing Enzymes and Biotransformation Reactions  2012).  
Cytochrome P450 superfamily enzymes are involved in the majority of reductive 
reactions and are reported to be responsible for the metabolism of ~70-80% of all the 
available drugs in the market (Zanger and Schwab 2013). Conjugation reactions in the liver 
are carried out by uridine diphosphate-glucuronosyltransferases (UGTs), sulfotransferases 
(SULTs), N-acetyltransferases (NATs), glutathione S-transferases (GSTs), amino acid 
conjugation enzymes and methyltransferases (Jancova et al. 2010; Appendix: Drug 
Metabolizing Enzymes and Biotransformation Reactions  2012). Majority of studies 
evaluating the effect of NAFLD on drug disposition proteins draw their conclusions from 




complex and heterogeneous alteration in drug metabolizing enzymes and transporters in 
human. Such discrepancies are partly due to species differences and lack of animal models 
which accurately reflect the complexity and pathophysiology of human disease.  
Studies in preclinical species 
Preclinical species have played a key role in our understanding of NAFLD 
(Santhekadur et al. 2018). Genetic as well as dietary animal models have been developed 
to understand the disease. Common genetic mice models of NAFLD include leptin-
deficient (ob/ob), leptin receptor-deficient (db/db) and low-density lipoprotein deficient 
mice. Even though low leptin levels are not observed in human NAFLD, leptin-deficient 
mice (ob/ob) represents obesity, hyperlipidemia and insulin resistance, steatosis but 
without fibrosis (Trak-Smayra et al. 2011; Canet et al. 2014). 
However, fibrosis can be induced in leptin receptor-deficient mice (db/db) from 
external stimuli. Low-density lipoprotein receptor-deficient mice (LDLR) exhibit a 
pathology similar to db/db mice and can develop fibrosis. But not all studies in mice models 
are consistent among different models, the results have shown to vary according to the diet 
and species.  (Kim et al. 2004; Yoshinari et al. 2006; Fisher et al. 2008). Dietary models 
are developed using methionine and choline-deficient (MCD) and hypercaloric diets 
(Stephenson et al. 2018). MCD models exhibit steatosis, inflammation, fibrosis similar to 
human disease but significantly differ in metabolic phenotype of the disease. MCD-fed 
mice show increased insulin sensitivity, significant weight loss, and low blood glucose. 
Similarly, hypercaloric diet (Western-like diet) model show steatosis, 




induced animal model of alcoholic fatty liver disease) and STAM (Stelic Animal Model) 
models are proposed to exhibit considerable similarity with human NAFLD in pathology 
and phenotype (Fujii et al. 2013; Asgharpour et al. 2016). Both the models gain weight and 
develop insulin resistance, steatosis, fibrosis, and hepatocellular carcinoma. Dietrich et al. 
have extensively discussed the pros and cons of different animal models of NAFLD 
(Dietrich et al. 2017).  
 Given the complexity of human disease, no single animal model to date fully 
recapitulates the human disease state (Dietrich et al. 2017). The failure of some compounds 
which showed a significant promise in preclinical studies has raised a concern about the 
inadequacies of animal models for the disease. ASP9831, a potent PDE4 inhibitor was 
being developed by Astellas Pharma to modulate cyclic adenosine monophosphate activity. 
Compared to placebo, ASP9831 drug failed to improve the biochemical parameters 
associated with NASH in a 12-week phase-II clinical trial (Ratziu et al. 2014). Similarly, 
resveratrol was unable to improve hepatic steatosis and insulin sensitivity at 
pharmacological doses in an 8-week study (Chachay et al. 2014).  
Studies in human 
Disease-mediated changes have been known to impact the abundance of drug 
disposition proteins in the liver, hence leading to altered drug profiles (Merrell and 
Cherrington 2011; Gandhi et al. 2012; Cobbina and Akhlaghi 2017; Evers et al. 2018). 
Theoretically, an alteration in DDPs could lead to undesirable pharmacokinetic and 
pharmacodynamic outcomes (figure 2).  Clinical studies in NAFLD are currently limited 




profile on therapeutic result in the disease state. Current literature on studies with human 
tissue is confounding with reports of increase, decrease or non-significant change in the 
activity, protein, and/or mRNA levels of clinically relevant hepatic cytochrome P450 
enzymes (table 2). Genome-wide studies (GWAS) in NAFLD patients found no significant 
changes in ADME proteins between normal and steatotic livers at mRNA expression level 
(Greco et al. 2008; Lake et al. 2011). However, mRNA-based studies do not account for 
the potential contribution of post-transcriptional and post-translational changes relevant to 
protein expression or enzyme activity. A comprehensive table of alteration in drug 
metabolism enzyme expression or activity is given in table 1. In general, a decrease in 
CYP3A4 and CYP2E1 activity appears to be dominant in the studies in subjects and human 
tissue (Merrell and Cherrington 2011; Woolsey et al. 2015; Cobbina and Akhlaghi 2017). 
Even though the effect of NAFLD on CYP450s has been extensively studied in vitro, our 
understanding of the disease associated impact on other DMEs is limited due to the scarcity 
of studies. Similar to CYP450s, differential regulation appears to be at play for other DMEs 
including UGT and SULTs in human NAFLD. Studies in human tissue found the minimal 
effect of NAFLD on UGT enzymes while a significant alteration was reported in hepatic 
sulfotransferase expression and activity (Hardwick et al. 2013). NASH mediated 
upregulation of UGT1A9, 2B10, and 3A1 mRNA was reported in human liver (Hardwick 
et al. 2013). It was also noteworthy that the protein expression of UGT1A9 and 1A6 
decreased in NASH (Hardwick et al. 2013). Elevated SULT1C4 mRNA was seen in NASH 
whereas SULT1A1 and 2A1 protein levels were lower in disease samples compared to 





Label-free mass spectrometry-based proteomics 
Traditionally, the level of expression is determined using Western blotting, but last 
decade has seen a rise in mass-spectrometry-based methods for quantification of proteins. 
Omics technologies have been used extensively in the quest to identify novel biomarkers 
for NAFLD (Pirola and Sookoian 2018). Targeted proteomics (SRSM, MRM) based 
approaches have also proven to be useful in quantification of DDPs. While the targeted 
quantification represents the most robust method of choice for absolute quantification, cost 
and significant time for optimization of mass spectrometer conditions for each targeted 
peptide limit its application to a few target proteins. 
In contrast, label-free quantification or more commonly known as LFQ has 
emerged recently as an alternative approach for comparative analysis of protein expression 
across different samples owing to fast and low-cost of this technique (Wong and Cagney 
2010). LFQ approaches are relatively inexpensive as compared to targeted MRM methods 
as there is no need to synthesize unique peptides for each protein and isotopically labeled 
isoforms of this peptide as the internal standard. Accurate and robust quantification with 
LFQ approaches is intricate, and different strategies for extracting quantitative data from 
LFQ analysis has been developed (Wong and Cagney 2010). A comprehensive cost 
comparison of various mass spectrometry-based techniques reported significant cost 
savings with label-free based quantitative proteomics (Al Feteisi et al. 2015).   
Studies have shown that protein expression is a better surrogate than mRNA for 
prediction of functional activity of cytochrome P450 enzymes. Data-dependent (DDA) and 
data independent analysis (DIA) are two common data collection modes in shotgun 




given retention time are selectively selected for fragmentation (MS/MS). Alternatively, the 
precursors are selected in a specific m/z range and are fragmented without any 
prioritization to their relative abundance. This approach offers a more comprehensive and 
complete analysis of samples than traditional DDA. SWATH-MS (sequential window 
acquisition of all theoretical mass spectra) is one such DIA technique that provides an 
alternative to DDA and targeted approaches for protein estimation (Gillet et al. 2012). As 
mentioned previously, SWATH is a DIA technique in which all the precursors within a 
predefined m/z are fragmented, and product ions of these precursors are recorded as a 
digital repository (Rosenberger et al. 2014). However, coeluting precursors and fragments 
at any given RT in DIA data make it difficult to select the correct peak without a robust 
spectral library. Therefore, a reference spectral library is often used for DIA and data are 
further deconvoluted and extracted using software like OpenSWATH, SWATH 2.0 and 
Skyline (Navarro et al. 2016). A significant advantage of SWATH-MS over the other mass 
spectrometry methods is related to the ability to perform retrospective mining of the data.  
The targeted protein extraction can be improved by expanding the coverage of reference 
spectral library and remining the DIA data. For instance, if the researcher comes up with a 
new hypothesis in the future, SWATH-MS data would allow interrogation of the existing 
data for additional protein/s of interest without the need for sample digestion or data 
reacquisition (figure 3). Such a strategy offers a tremendous benefit concerning the saving 
of sample, time and money.  
Absolute protein concentrations are vital to simulate drug exposure using 
physiologically based pharmacokinetic (PBPK) models. However, despite all the 




can’t be determined using techniques like SWATH-MS. Alternatively, a spike in standard 
or targeted approach for a protein of interest would be needed to determine the protein 
levels. Global proteomics using DDA data and “total protein approach (TPA)” can be 
instead used to estimate protein concentrations. TPA is widely accepted and delivers 
protein concentrations without the need for the isotope-labeled spike in reference peptides 
(Wisniewski et al. 2014). TPA assumes that a protein’s abundance with a cell as a fraction 
of total protein is approximately the same as the proportion of its MS signal to the total MS 
signal of the cell. 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 =  






  The absolute protein concentration (p), expressed as mol/g of total protein can further be 
calculated using equation 2 (Wisniewski and Mann 2016). MW (p) is the molar mass of 
protein.  
𝑝 =
 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑝)
𝑇𝑜𝑡𝑎𝑙 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 × 𝑀𝑊(𝑝)
 
 
Physiologically based pharmacokinetic (PBPK) model 
While there is a significant amount of literature is available for the levels of these 
proteins in healthy people, little is known about how NAFLD changes the concentration of 
these enzymes in the human liver. The information is essential to determine the influence 
of the disease on the drug disposition, but clinical studies in NAFLD subjects are limited. 
The use of physiologically based pharmacokinetic models for prediction of 




increasing in popularity (Sager et al. 2015). PBPK modeling is a bottom-up simulation 
approach which takes in account multiple parameters specific to the drug, physiology of 
the species (different organs represented as compartments) and an understanding of the 
pharmacokinetic properties of the drug of interest (Zhuang and Lu 2016). System or 
dependent population parameters which are essential for prediction of exposure and include 
hepatic blood flow and enzyme or transporter abundance among others. Drug-dependent 
parameters are derived from physicochemical properties of the molecules and rest are 
determined from in vitro studies (protein binding, metabolism, enzyme kinetics, intrinsic 
clearance, etc.). An exhaustive list of different parameters required for building a PBPK 
model is discussed elsewhere (Zhuang and Lu 2016).  
In vitro and in vivo parameters which accurately reflect the human disease are vital 
to predict and simulate in silico drug exposure. Some commercial PBPK platforms like 
GastroPlus (Simulation Plus Inc.), Simcyp (Certara L.P.)  PKSIM (Bayer), CloePK (Evotec 
A.G.) are currently available. PBPK models for NAFLD are presently not available in 
different simulation platforms. A lack of sufficient in vitro and in vivo data is a significant 
hurdle in the development of PBPK models for NAFLD.  
Hepatic blood flow is a critical parameter determining the rate of presentation of 
the drug for its metabolism in the liver. Hepatic portal vein (HPV) supplies 70% whereas 
hepatic artery (HA) is responsible for ~30% of the blood reaching the liver. HPV supplies 
liver with nutrients and xenobiotics (drugs) absorbed in the GI tract and HA is responsible 
for carrying oxygen. Fat-accumulation in hepatocytes was found to correlate with 
decreased HPV blood flow in NAFLD patients (Shigefuku et al. 2014). Hepatocyte 




intrasinusoidal volume and microvascular blood flow (Farrell et al. 2008). Impaired 
systemic circulation and modification of cellular membrane may also interrupt oxygen 
availability in NAFLD leading to hypoxia and accelerated lipid droplet formation (Anavi 
et al. 2017). Blood flow change in early fibrosis was attributed to outflow blockage in the 
liver sinusoidal area (Hirooka et al. 2015). The changes in hepatic blood flow during 
different stages of NAFLD is given in table 3 (Shigefuku et al. 2012).  
Concluding remarks 
The epidemic of NAFLD is upon us, and a widespread effort is currently underway 
to address different aspects of this multifaceted and complex metabolic disease. A lack of 
good preclinical models to recapitulate the spectrum of the disease remains a significant 
challenge and care should be taken when extrapolating results from preclinical species to 
human. Risk of alterations in the drug disposition proteins remains high in NAFLD due to 
significant structural and pathophysiological changes in the liver, the primary organ for 
drug disposition. PBPK has been used in recent past to simulate the exposure of various 
drugs in special populations. However, most of our understanding of these models comes 
from research done in healthy individuals, but little is known about the physiological as 
well as pharmacokinetic parameters of drugs in NAFLD. Moreover, after drug 
administration, there is also a need to understand how drug disposition proceeds in these 
disease/target populations. Two of the critical parameters governing the exposure include 
enzyme kinetics and expression of proteins involved in the disposition of the compound. 
There is also a need of predictive biomarkers for NAFLD to delineate NASH from NAFL 
in human and mass spectrometry-based proteomics may hold promise to fill this gap. In 




the proteins involved in the disposition of the drugs. Additionally, to improve translation 
ability and accuracy of simulation models, it is essential to understand how the 
pharmacokinetics and other physiological parameters change in NAFLD.  
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Figures and tables 
Figure 1: Hematoxylin and Eosin staining of liver samples (A) Normal liver with 
uniform chord-like arrangements of hepatocytes, (B) Nonalcoholic fatty liver (NAFL) liver 
with lipid droplets, and (C) Nonalcoholic steatohepatitis (NASH) with significant hepatic 
steatosis and infiltration of lymphomononuclear inflammatory cells.  
Figure 2: Effect of altered CYP3A4 on systemic midazolam exposure. The systemic 
exposure of a substrate may increase if the CYP450 responsible for its metabolism and 
clearance is reduced. The opposite is true when the expression is increase. The illustration 
shown here for CYP3A4 mediated midazolam (MDZ) in normal and altered states.  1’OH-
MDZ: 1-hydroxy midazolam. 
Figure 3: Graphical illustration of the advantage of SWATH-MS over traditional 
MRM based quantification method. MRM, Multiple reaction monitoring; SWATH-MS, 
Sequential windowed analysis of all the theoretical mass spectra.   
Table 1: Therapeutic agents currently being developed for treatment of NAFLD. 
ACC, Acetyl-CoA Carboxylase; AOC, amine oxidase, copper containing; ASK, Apoptosis 
signal-regulating kinase; FGF, fibroblast growth factor; FXR, Farnesoid X receptor; 
PPAR, peroxisome  proliferator-activated receptors; mTOT, mitochondrial target of 
thiazolidinediones; SGLT, Sodium-dependent glucose cotransporter; GLP, Glucagon-like 
peptide; ASBT, apical sodium–bile acid transporter; ASK, apoptosis signal-regulating 
kinase; THB, thyroid hormone receptor 
Table 2: Altered expression and activity levels of CYP450 enzymes in NAFLD. CYP, 
cytochrome P450; NASH: Nonalcoholic steatohepatitis 
Table 3: Hepatic blood flow changes in different stages of NAFLD. Liver blood flow 
in the disease state were studied using xenon computed tomography. THBF: Total hepatic 
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NAFLD ↑   (Kohjima et al. 2007) 
NAFLD   ↔ (Prompila et al. 2008) 
NAFLD   ↓ (Nakamuta et al. 2005) 
NAFLD 
progression 
↓ ↓ ↔ (Fisher et al. 2009) 
NASH ↑   (Baker et al. 2010) 
NASH   ↑ (Chalasani et al. 2003) 
NASH   ↑ (Orellana et al. 2006) 
NASH   ↑ (Orellana et al. 2006) 
NASH  ↑  (Weltman et al. 1998) 
NASH  ↑  (Niemela et al. 2000) 
NAFL   ↔ (Donato et al. 2006) 
NAFL ↑   (Emery et al. 2003) 
CYP3A4/5 
NASH ↔ ↓ ↓ (Jamwal et al. 2018) 
NAFL ↔ ↓ ↓ (Jamwal et al. 2018) 
NAFLD 
progression 
↔ ↔ ↔ (Fisher et al. 2009) 
NAFLD  ↔  (Bell et al. 2010) 
Hepatocytes   ↔ (Donato et al. 2006) 
Steatosis   ↔ (Donato et al. 2007) 
NASH  ↑  (Niemela et al. 2000) 
NASH  ↓  (Weltman et al. 1998) 




↔ ↓ ↓ (Fisher et al. 2009) 
NAFL   ↓ (Donato et al. 2006) 




↑ ↑ ↑ (Fisher et al. 2009) 
NASH ↓   (Rubio et al. 2007) 




↑ ↔ ↔ (Fisher et al. 2009) 
NASH ↓   (Stepanova et al. 2010) 












↔ ↓ ↓ (Fisher et al. 2009) 
 





ml/min/100 g Normal  NAFL  
Early 
NASH  
Advanced NASH  
THBF 94.0±17.8 66.4±10.6 52.4±12.3 47.1±13.2 
PVBF 72.4±16.2 41.6±5.6 33.6±7.0 28.4±6.3 
HABF 21.2±7.4 24.8±8.5 18.7±7.0 18.7±8.4 
 (Carlisle et al. 1992) (Shigefuku et al. 2012) 
Table 3: Changes in hepatic blood flow in different stages of nonalcoholic fatty 
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We describe a sequential windowed acquisition of all theoretical fragment ion mass spectra 
(SWATH-MS) based method for label-free, simultaneous, relative quantification of drug 
metabolism enzymes in human liver microsomes (HLM; n=78).  In-solution tryptic 
digestion was aided by a pressure cycling method which allowed a 90-min incubation time, 
a significant reduction over classical protocols (12-18 h).  Digested peptides were separated 
on an Acquity UHPLC Peptide BEH C18 column using a 60-min gradient method at a flow 
rate of 0.100 mL/min.  The quadrupole-time-of-flight mass spectrometer (ESI-QTOFMS) 
was operated in positive electrospray ionization mode and data was acquired by Data-
Dependent Acquisition (DDA) and SWATH-MSALL mode.  A pooled HLM sample was 
used as quality control to evaluate variability in digestion and quantification among 
different batches, and inter-batch %CV for various proteins was between 3.1-7.8%. 
Spectral library generated from the DDA data identified 1,855 distinct proteins and 25,601 
distinct peptides at a 1% global false discovery rate (FDR). SWATH data were queried and 
analyzed for 10 major cytochrome P450 (CYP) enzymes using Skyline, a targeted data 
extraction software. Further, correlation analysis was performed between functional 
activity, protein and mRNA expression for ten CYP enzymes.  Pearson correlation 
coefficient (r) between protein and activity for CYPs ranged from 0.314 (CYP2C19) to 
0.767 (CYP2A6). A strong correlation was found between CYP3A4 and CYP3A5 
abundance and activity determined using midazolam and testosterone (r>0.600, p<0.001). 
A moderate protein-to-activity correlation (r>0.500, p<0.01) was also observed for 
CYP2A6, CYP1A2, CYP2C9, CYP2B6 and CYP2E1. The correlation for CYP2C8, 




the suitability of SWATH-MS based method as a valuable and relatively fast analytical 
technique for relative quantification of proteins in complex biological samples. We also 

























Hepatic drug metabolizing enzymes (DMEs) are responsible for the clearance of 
pharmacological agents and xenobiotics.  The abundance of these enzymes in liver tissue 
determines the rate and extent to which drugs are metabolized and cleared from systemic 
circulation. Cytochrome P450s (CYPs) and uridine diphosphate glucuronyltransferases 
(UGTs) constitute the majority of phase I and phase II DMEs, respectively (1).  CYPs are 
primarily involved in the oxidation of endogenous steroids, xenobiotics, and drugs (2, 3).  
Expression of CYPs thus impacts drug disposition, pharmacokinetics and adverse drug 
reactions (1).  Characterization of expression and activity of DMEs in human liver 
microsomes and hepatocytes is a pivotal part of drug development.  Moreover, induction 
potential of new chemical entities is typically screened using primary or cryopreserved 
hepatocyte culture (4).   
It is important to understand how the level of different DMEs changes from one 
individual to another or how different disease states influence the abundance of these 
enzymes. Classical methods for protein quantification include Western blotting and ELISA 
(5).  Western blotting is semi-quantitative, low throughput, labor intensive, and require the 
use of expensive antibodies (6).  ELISA methods can be higher throughput and more 
quantitative than Western analysis, but this approach is also labor intensive, suffers from 
limited concentration range and can lack specificity (6).  In the recent years, protein mass 
spectrometry has proved to be a powerful technique in different areas of biomedical 
research including in drug development (7).  “Targeted” or “absolute” protein 
quantification methods use liquid chromatography coupled with a triple quadrupole mass 




per protein (8).  These peptides are custom synthesized and are often paired with an isotope-
labeled peptide as an internal standard.  Several groups have used high-resolution mass 
spectrometry methods to analyze the expression of drug-metabolizing enzymes and 
transporters in human tissue (3, 9). Traditionally, in the drug metabolism field, multiple-
reaction monitoring (MRM) method has been used for absolute quantification of clinically 
relevant CYPs and UGTs in human liver tissue (10-12). Others have measured the 
concentration of drug transporters using quantitative targeted proteomics (13).  However, 
significant upfront assay development with 1-2 synthetic peptides for each protein is often 
required for targeted MRM methods developed to ensure detection of multiple transitions. 
Label-free quantification (LFQ) techniques are now becoming common for analysis of 
proteins using mass spectrometry.  Neilson et al. published a comprehensive review on 
LFQ approaches and compared it with other labeling based techniques (14).  Sequential 
windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) is a cost 
efficient, LFQ method that combines data-independent acquisition (DIA) and multiple 
reaction monitoring-like data processing for accurate peptide quantitation.  It provides an 
advantage when compared to traditional mass spectrometry-based proteomics methods like 
shotgun (high throughput) and SRM (high reproducibility and consistency). The technique 
enables a complete and permanent recording of all fragment ions of the detectable peptide 
precursors present in a digested biological sample that can be interrogated retrospectively 
for peptide features for SRM-like quantitative information, time-consuming design of 
acquisition method (15).  Data are acquired on the high-resolution time of flight mass 
spectrometer (TOF/MS) in consecutive continuous cycles through precursor isolation 




data contain the spectra of fragment ions for all precursor ions that appear within the 
defined precursor retention time and m/z space.  The combination of all the high-resolution 
spectra collected at ≥25,000 resolution (FWHM) generates a fragment ion map which 
generates extracted ion chromatogram (XIC) measurements with high specificity derived 
by low mass error (15). This provides an unbiased quantification method which is 
reproducibly collected across all samples for relative quantitation and does not require a 
protein or sample specific method development. Peptide spectral library can be used for 
extraction of peptides of interest from the SWATH data and further statistical analysis.  
The purpose of this work was to develop a SWATH-MS method for relative 
quantification of proteins in the microsomal fraction of 78 human liver tissue samples. 
Enzyme activities of DMEs as provided by the vendor were correlated with protein level 
determined in the human liver microsomes by using the current method.  Additionally, we 
performed correlation analysis between protein and mRNA expression with enzyme 













MATERIALS AND METHODS 
Chemical and Reagents 
Trypsin digested β-galactosidase (E. coli), protein preparation kit and TPCK-treated 
trypsin were procured from AB Sciex, Framingham, MA. Mass spectrometry grade 
acetonitrile and formic acid were from ThermoFisher Scientific, Waltham, MA.  Acquity 
UHPLC Peptide BEH C18 analytical column and VanGuard pre-columns were from 
Waters Corp., Waltham, MA. RNeasy Mini Kit was purchased from Qiagen Inc., Valencia, 
CA. 
 
Human liver microsomes 
Human liver tissues retrieved from brain dead individuals by Sekisui Xenotech were 
used in this study. A brief overview of the donor demographics was given in table 1.  
Human liver microsomes (HLM) were prepared as described previously, with 
modifications (16). 
Briefly, human liver samples were carefully thawed on ice and weighed. Tissue was 
immediately transferred to a pre-cooled 7 mL homogenization bead-mill tube containing 
50 mM Tris-HCl (pH 7.4) buffer having 0.5 mM EDTA, 0.25 M sucrose and 20 µM 
BHT (3 mL/g wet liver weight) and homogenized using a bead homogenizer (Bead 
Ruptor 24, Omni International, Kennesaw, GA). Homogenate was centrifuged at 10,000 
g for 20 min at 4°C (Eppendorf 5810R, Eppendorf AG, Hamburg, Germany). The pellet 
containing cell debris was discarded, and supernatant (S9 fraction) was ultra-centrifuged 
at 100,000 g for 1 hour at 4°C (Beckman Coulter, Brea, CA). Further, the supernatant 
was separated and stored as a cytosolic fraction for future use. The pellet on the walls 




homogenization buffer containing 20% glycerol (pH 7.4, 0.66 mL/g of tissue). The 
contents were carefully transferred to a 1 mL Dounce homogenizer for fine 
homogenization. The resulting microsomal fraction was stored at -80°C until analysis. 
Microsomal protein concentration was estimated using a bicinchoninic acid method 
(Pierce-Fisher, Rockford, IL) with bovine serum albumin as a standard. The samples 
were diluted to 2.5 mg/mL in phosphate-buffered saline (pH 7.4) before protein 
digestion as described below. XTreme 200 pool HLM was purchased from Sekisui 
XenoTech, LLC, Kansas City, KS. 
 
Pressure cycling technology (PCT) based protein digestion  
In-solution trypsin digestion was performed on each biological sample in duplicates 
according to a published method with modifications (17). Denaturation, reduction, and 
alkylation were performed in centrifuge tubes while digestion was carried out in 
MicroTubes (Pressure BioSciences Inc., South Easton, MA) under oscillating high-
pressure cycles in a Barocyler NEP2320-45k (Pressure BioSciences Inc.). Briefly, 150 
µg of microsomal protein was denatured and reduced for 1 h at 60°C in a shaking water 
bath (75 rpm). Reduced samples were alkylated for 10 min at room temperature to 
prevent free cysteine residues from the reformation of peptide bonds.  Subsequently, 
samples were diluted with equal volume of 100 mM Tris buffer (pH 8) containing 4 mM 
MgCl2 and digested with TPCK-treated trypsin (protease: protein, 1: 20) in the 
barocycler.  PCT-aided digestion was performed at 50 °C for 90 cycles, 50 s at 35 kpsi 
and 10 s at ambient pressure for every cycle.  Further, samples were transferred to a 




concentration of 0.1%.  The mixture was vortex-mixed for 10 s before centrifugation at 
5,000 rpm for 1 min at 10°C. The supernatant was collected and transferred to a clean 
micro-insert for further analysis.  Two technical replicates for each HLM sample were 
digested and analyzed by mass spectrometry.  XTreme 200 pool sample was used as 
digestion control to monitor the batch-to-batch variation of protein digestion carried out 
in 6 batches. Approximately 12 samples and one digestion control sample were digested 
and run in every batch along. 
 
LC-QTOF/MS analysis 
All experiments were performed on a Sciex 5600 TripleTOF® mass spectrometer 
equipped with a DuoSpray™ ion source (AB Sciex, Concord, Canada) coupled to 
Acquity UHPLC HClass system (Waters Corp., Milford, MA, USA).  The mass 
spectrometer was operated in positive electrospray ionization mode for the analysis. The 
peptides were separated on Acquity UHPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 
1.7 µm) equipped with Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). 
Digested samples were maintained at 10°C in the autosampler and the analytical column 
temperature was kept at 40°C. The amount of protein per injection on the column was 
10 µg. The chromatographic separation was achieved with a runtime of 60 min at 100 
µL/min with a gradient method using mobile phase A (98% water, 2% acetonitrile, 0.1% 
formic acid) and mobile phase B (98% acetonitrile, 2% water, 0.1% formic acid). A 
linear gradient scheme was used with solvent composition as follows; 98% A from 0-3 
min: 60% to 90% A from 3-48 min: 20% A held from 49-52 min to flush the column, 




before the start of next run. In each batch, trypsin-digested β-galactosidase peptides were 
injected (~30 pmol/injection) every 10 samples during the analysis to monitor mass 
calibration of the TOF detector and normalization of intensity during relative 
quantification. The average intensity of all the β-galactosidase peptide samples in a 
batch was used for data normalization of the respective batch of samples.  
 
Standard DDA and SWATH-MS data acquisition 
Mass spectrometry analysis was performed according to a previously described 
method with modifications (18). Analyst® TF 1.7 was used to acquire data during the 
study (AB Sciex, Framingham, MA).  DDA was used to acquire data for generation of 
peptide ion library, and SWATH-MSALL mode for relative quantification of the proteins.  
Positive ionization monitoring was utilized for all the experiments during the study.  
DDA experiments were performed over a mass range of m/z 350-950 and all ions 
exceeding 350 cps, with a charge state 2 to 4, and quadrupole resolution of 0.7 AMU 
was used for automated MS/MS analysis. The mass tolerance was set at 50 mDa during 
the initial 250-milliseconds (ms) survey scan, and 8 ions were selected for product scan 
per cycle (total cycle time: 900-ms). A DuoSpray™ ion source was used for all the 
experiments.  Source specific parameters settings for the analysis were ion source gas 1 
(GS1): 55 psi, ion source gas 2 (GS2): 60 psi, curtain gas (CUR):25 psi, source 
temperature (TEM): 500°C, and ionspray voltage floating (ISVF):5500 V. Compound-
specific parameters for acquisition were declustering potential (DP): 120, and collision 
energy (CE): 10 (product ion experiments were carried out using rolling collision 




SWATH window width of 25 m/z resulting in 20 overlapping mass windows per cycle. 
Accumulation time of 109 ms per window was used which resulted in a total cycle time 
of 2.29 s. Rolling collision energy for +2 and +3 charges with collision energy spread 
of 15 V was applied to each SWATH window upon automatic calculation of the collision 
energy center value, dependent on the m/z range according to this rolling collision 
energy equation; CE = 0.044*(m/z)+9 (19). 
 
Generation of spectral library 
Protein database searching was performed against reference UniProt human 
proteome library (July 2015) by ProteinPilot 5.0 (AB Sciex; Framingham, MA, USA) 
using Paragon™ algorithm (5.0). A comprehensive spectral library of protein and 
peptides from DDA runs of the HLM samples was prepared. Data were uploaded to 
ProteinPilot Software to carry out protein identification against a Human Uniprot 
FASTA database. Search parameters in ProteinPilot were as follows: Cys alkylation-
MMTS; digestion-Trypsin; instrument, TripleTOF® 5600; ID focus-Biological 
modifications, search effort-Thorough ID, detected protein threshold-0.05 (10%), and 
false discovery rate analysis - yes. The resulting library file (*.group) was uploaded to 
Skyline and label-free analyses of data was performed as described below. The spectral 
library is available on PeptideAtlas (Identified number PASS01078).   
 
Data processing using Skyline 
Skyline is an open source, Windows-based software for creating and analyzing data 




retrieved from Uniprot and uploaded onto Skyline. Detailed Skyline and data processing 
settings are given in supplementary information I. 
Briefly, spectral library generated from DDA files was uploaded in Skyline, and 
SWATH-MS data files were processed using the full scan MS/MS filtering at a resolution 
of 10,000. Unique, non-repetitive peptides were refined and curated for reproducible 
fragment ions, and peak boundaries for each selected peptide were manually supervised 
and when necessary, adjusted.  The reproducibility and reliability of selected peptide and 
transitions were verified visually by looking at the peak area ratio of the ion across the 
samples. We used 2 peptides per protein and 3 fragment ions per peptide for every protein. 
Selected peptides for each protein for the relative quantification of the CYPs described in 
this study were also correlated (protein specific) to validate the selection of peptides 
(supplementary figure 1). 
The total area of representative peptides for a protein was summed, and resulting 
intensity was normalized by total intensity of tryptic peptide of β-galactosidase. 
MultiQuant v 3.0 (AB Sciex, Framingham, MA) was used to retrieve intensity for 
APLDNDIGVSEATR peptide [(M+2H)2+: 729.365] and was subsequently used for 
normalization among different batches as described above (supplementary information II) 
(21). Percent coefficient of variation (CV%) of the proteins of interest (CYPs) between 6 
batches was calculated and plotted using Prism 6.0 (GraphPad Inc., La Jolla, CA). Peptides 
used for relative quantification and the transitions for precursor and product ions are given 






Quantification of hepatic mRNA expression 
Total cellular RNA was isolated from the samples using RNeasy Mini Kit (QIAGEN 
Inc., Valencia, CA). The total RNA was reverse‐transcribed, and the single-stranded 
DNA was used for real‐time PCR. The mRNA expression of hepatic CYP was quantified 
in duplicates by real‐time PCR using an Applied Biosystems 7500 real-time PCR system 
(Applied Biosystems) according to the manufacturer’s instructions. 18S ribosomal RNA 
(rRNA) was also quantified as an internal control. The primers used for CYPs are given 
in supplementary information III. 
Correlation and statistical analysis: Enzyme activity, protein, and mRNA expression 
Enzymatic activity for 10 CYPs provided by Xenotech was used for correlation with 
the relative protein abundance estimated in HLM using the current method. The correlation 
analysis was also performed with mRNA levels determined from liver samples using 
method as described above. The incubation conditions, probe substrates and other details 
of the enzymatic assays performed by Xenotech on the livers are given in supplementary 
information IV.  Information on mRNA probes is provided in supplementary information 
III. A three-way correlation analysis was conducted between enzyme activity, protein 
levels, and mRNA (described below).  
Normality tests were performed before statistical analysis and to address the skewness, 
the data were natural log transformed (ln) before correlation analysis. Pearson correlation 
coefficient was used to determine the relationship between activity, protein and mRNA 
level. Correlation coefficient (r)>0.600 was considered strong while between 0.400-0.600 
was considered moderate. Additionally, any correlation with r<0.400 was considered poor 




statistical analysis was performed with SPSS 24 (IBM Corp., Armonk, NY) and graphs 


























Targeted data extraction using Skyline 
At a critical FDR of 1.0%, we detected 1855 distinct proteins and 25,681 distinct 
peptides from global FDR fit (Figure 1 (a-b).  The in-house generated spectral library was 
imported into Skyline, and data extraction was performed. The list of peptides and their 
transitions along with charge state is provided in supplementary information II.  The 
correlation analysis of two peptides for a protein is given in supplementary figure 1. Out 
of the 15 hepatic CYPs reported for xenobiotic metabolism, we were able to find 12 CYPs 
in this study (22). Inter-batch %CV for all the DMEs evaluated from quality control sample 
ranged from 3.1 to 7.8% (supplementary figure 2).  
Correlation between protein expression and enzyme activity 
Pearson correlation coefficient (r) for CYPs ranged from 0.314 (CYP219) to 0.767 
(CYP2A6). All the major CYP enzymes showed a significant (p<0.05) correlation between 
enzyme activity and protein levels (Figure 2 (a-l). CYP3A4 and CYP3A5 abundance, and 
activity determined using midazolam and testosterone showed a significant association 
(r>0.650, p<0.001). A moderate protein-to-activity correlation (r=0.400-0.600, p<0.001) 
was also observed for CYP2A6, CYP1A2, CYP2C9, CYP2B6 and CYP2E1. The 
correlation for CYP2C8, CYP2D6 and CYP2C19 was significant but poor (r<0.400, 
p<0.05). A detailed correlation between activity and protein is provided in Table 2. 
Correlation between mRNA expression and enzyme activity 
The correlation coefficient for mRNA and activity ranged from -0.067 to 0.729 (Figure 




significant. The correlation between mRNA expression and activity for CYP3A4, 
CYP1A2, CYP2A6, CYP2C8, and CYP2B6 showed a significant and moderate correlation 
(r=0.400-0.600, p<0.01). CYP3A5 mRNA correlated significantly only with midazolam 
hydroxylation activity. CYP2D6 exhibited a poor but significant correlation (r=0.306, 
p<0.05). The correlation was poor and insignificant for other CYP isoforms. A detailed 
correlation table is provided in Table 2. 
Correlation between mRNA and protein expression 
We found that only CYP2A6 (r=0.395), CYP1A2 (r=0.271), CYP3A4 (r=0.577) and 
CYP2B6 mRNA (r=0.431) levels showed a correlation which was statistically significant 
(Figure 4 (a-j).  There was some correlation (r<0.200) between CYP2C9 and CYP2C19 
mRNA and protein level but did not reach statistical significance.  All other isoforms 
showed a poor correlation between mRNA and protein which was again not significant 















Studies involving drug metabolizing enzymes (DMEs) are critical for evaluating drug 
efficacy and safety. Thus, an understanding of the biological variation of these DMEs could 
provide useful insight into pharmacokinetics or drug interaction potential of new chemical 
entities. Conventional targeted methods for protein quantification rely on the use of 1 or 2 
unique peptides per protein. The data are further acquired using MRM, and a ratio of 
unlabeled (light) to labeled peptide (heavy) is used to determine the level of that peptide 
present in a digested sample (23).  However, a researcher would require a separate isotope-
labeled peptide for each target peptide, and this leads to a significant cost.  These high-
purity isotope-labeled synthetic heavy peptides cost anywhere from $700 to $1,000 for ∼1 
mg of peptides with concentration certification by amino acid analysis.  For the 
development of small numbers of assays, this is a reasonable investment.  However, the 
cost can be prohibitive when the numbers of proteins of interest exceed a limited number 
or for experiments intended for biomarker discovery.  In drug metabolism, usually only 
high abundance CYPs are measured using targeted approach and the low abundance CYPs 
or other microsomal enzymes are neglected. 
SWATH-MS has found an important application is the discovery of novel biomarkers 
(24, 25). Drawbacks of traditional MRM based approaches of protein quantification make 
it unsuitable for the research area (26). Ortea and colleagues used SWATH-MS for mining 
potential protein biomarkers of lung adenocarcinoma (27). Quantitative mapping of ErbB2, 
a receptor tyrosine kinase biomarker was recently demonstrated using SWATH-MS 




Pressure cycling technology (PCT) based digestion along with SWATH-MS 
acquisition (PCT-SWATH) was used to reduce the sample preparation time (17). The 
typical incubation time for digestion with trypsin is time-consuming and range from 12-18 
h (usually overnight). PCT enhances proteolytic action by inducing denaturation of 
proteins, therefore allowing better access to trypsin for cleavage sites (29). This also 
significantly reduces the digestion and overall sample preparation time. 
Skyline is a popular tool used for targeted data analyses of mass spectrometry data. It 
supports spectral library generation as well as data analyses of SWATH-MS files (20). Like 
other LFQ approaches, it relies on retention time (RT) alignment between the data files and 
the spectral library. A commonly used method for retention time normalization relies on 
the use of synthetic iRT peptides which are spiked to ever sample before analysis and has 
few drawbacks (30). Complex and widely different matrix might significantly affect the 
ionization and retention time reproducibility of these peptides within their LC retention 
time space and would compromise the evaluation of peptide peak area and FDR calculation 
in the case of a low signal within background noise. After thorough literature review and 
taking into consideration the costs associated with insertion of standards for RT 
normalization, we used the method suggested by Parker et al. (2016) and Nakamura et al. 
(2016) in recent articles (21, 30). A retention time predictor was created from endogenous 
peptides present in our sample using Skyline allowing integration of fragment intensity 
over different batches.  
Correlation between mRNA expression, protein abundance, and functional activity are 
not always tight due to complex regulation mechanisms involving pre and post-




events (31). Among other mechanisms, stability and half-life of protein and mRNA in their 
in vitro conditions also contribute to poor correlation (31). Similar mechanisms also dictate 
the correlation between protein and activity. Further, a poor selection of peptides for 
quantification can also affect the outcome of correlation analysis.  
In this work, we found that protein levels are better surrogates for estimating the 
activity of major xenobiotic CYP isoforms than mRNA. Additionally, we observed that 
both protein, as well as mRNA, can be used to access the functional activity of CYP2A6, 
CYP1A2, CYP2B6, CYP2C8 and CYP3A4.  Interestingly, apart from CYP3A4, CYP1A2, 
CYP2B6 and CYP2A6, protein expression of none of the other six CYP isoforms showed 
a significant correlation with the mRNA expression. Pre-translational regulation of 
CYP1A2, CYP3A4 and CYP2B6 expression has already been reported to be responsible 
for good correlation between mRNA expression and enzyme activity (32). 
Al Koudsi et al. found that CYP2A6 protein determined by Western blotting 
significantly correlate with nicotine C-oxidation activity in human livers (33). We also 
observed a significant correlation between protein, activity, and mRNA for CYP2A6. The 
correlation was in general stronger between activity and protein expression, followed by 
activity and mRNA. Similar correlations have been published previously for microsomal 
CYP2A6 (33).  
CYP3A activity for testosterone and midazolam hydroxylation correlated strongly with 
mRNA as well as protein. There was a good correlation between CYP3A4 mRNA, protein, 
and activity suggesting that both protein, as well as mRNA could be used to estimate the 
functional activity of this enzyme. Similar results on the correlation of CYP3A4 activity 




correlated strongly with midazolam and as well as testosterone hydroxylation (r>0.600, 
p<0.05). In contrast, the correlation between CYP3A5 mRNA and activity was poor for 
testosterone activity (r<0.188, p>0.10) while it was significant for midazolam activity 
(r=0.330, p<0.01). There was no relationship observed between protein levels and mRNA 
(r<0.100, p>0.10). 
As previously reported, CYP2E1 activity correlated strongly with protein level but not 
with the mRNA expression (34, 35). This again highlights the role of post-translational 
modifications of protein on the enzyme activity. Conversely, a pharmacogenomics study 
of CYP1A2 in human liver samples (n=150) found that mRNA and protein correlated with 
the functional activity of this enzyme (36). The results are in line with the significant 
correlation observed for CYP1A2 in our studies also. 
CYP2C9 metabolic activity was shown to have a higher correlation with protein than 
mRNA (32). This agrees with our findings for strong CYP2C9 protein and activity 
correlation (r=0.620, p<0.001). However, we insignificant correlation for mRNA with 
CYP2C9 activity and protein levels.  Interestingly, CYP2B6 and CYP2C8 activity showed 
a better correlation with mRNA than protein levels. It was not unexpected as Ohtsuki and 
colleagues have earlier reported that mRNA is a better surrogate than protein level for 
prediction of CYP2B6 activity (3). For CYP2B6, our data agree with finding as we also 
found a strong correlation (r=0.729, p<0.001) between mRNA and activity while there was 
a moderate correlation (r=0.533, p<0.001) between activity and protein. The correlation 
between CYP2B6 protein and mRNA was also moderate (r=0.431, p<0.001). Genetic 
polymorphisms were previously suggested to be responsible for such correlation 




also reported that the genetic polymorphism in CYP2C8, CYP2C19, and CYP2D6 account 
for major variability in the activity of these enzymes (38). Protein stability in isolated 
microsomes could also be attributed to poor correlation with mRNA. 
Rodríguez-Antona et al. observed a moderate correlation between CYP2C8 protein 
abundance and enzyme activity (39).  CYP2C8 activity correlated moderately with protein 
(r=0.331, p<0.01) but a strong correlation was observed with mRNA (r=0.524, p<0.01) 
suggesting the role of post-translational modifications.  A significant correlation between 
mRNA and activity for CYP2C8 and CYP2D6 suggests the utility of mRNA for studying 
the functional activity of these CYP isoforms. Poor correlation of CYP2C19 mRNA and 
activity suggest towards major post-translational changes influencing its activity in human 

















SWATH-MS exemplify a powerful LFQ technique, which addresses the limitations of 
the shotgun and targeted proteomics to provide a permanent digital repository of all 
peptides present in a sample.  This method can serve as a valuable post hoc tool for studying 
new hypothesis and ideas without the need to re-acquire data.  To the best of our 
knowledge, this is the first report demonstrating the use of SWATH-MS and pressure-
cycling based digestion for relative quantification of drug metabolizing enzymes in human 
liver microsomes and the correlation with their functional activity and mRNA expression. 
The studies also highlight the importance of protein levels for prediction of the functional 
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Table 1: Brief demographic summary of donors 
Total number of donors (Male/Female) 78 (41, 37) 
Ethnicity (C/AA/H) 66, 9, 3 
 Mean ± SD 
Age (years) 51.5 ± 12.9 
Weight (kg) 90.6 ± 27.2 
Height (cm) 169.6 ± 10.9 











Figure 1 : Identified proteins and peptides at 1% false discovery rate (FDR). The graph 
depicts identification of 1855 proteins and 25681 peptides in the spectral library at 1% 
FDR.  
Figure 2 (a-l): Correlation plots for relative protein expression and enzyme activity. 
Protein abundance values were expressed relative to APLDNDIGVSEATR peptide from 
E. coli β-galactosidase. The enzyme activity was represented as CYP-specific product 
formation/min/mg protein. All values are natural logarithm (ln) transformed and Pearson 
correlation analysis was performed.  
Figure 3 (a-l): Correlation plots for mRNA and enzyme activity. Messenger RNA 
(mRNA) was expressed relative to β-actin. Protein abundance values were expressed 
relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. The enzyme activity 
was represented as CYP-specific product formation/min/mg protein. All values were 
natural logarithm (ln) transformed and Pearson correlation analysis was performed.  
Figure 4 (a-j): Correlation plots for mRNA and protein expression. Messenger RNA 
(mRNA) was expressed relative to β-actin. Protein abundance values were expressed 
relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. All values are 






Figure 1: Identified proteins and peptides at 1% false discovery rate (FDR). The graph 






Figure 2 (a-l): Correlation plots for relative protein expression and enzyme activity. 
Protein abundance values were expressed relative to APLDNDIGVSEATR peptide from 
E. coli β-galactosidase. The enzyme activity was represented as CYP-specific product 
formation/min/mg protein. All values were natural logarithm (ln) transformed before 





Figure 3 (a-l): Correlation plots for mRNA and enzyme activity. Messenger RNA 
(mRNA) was expressed relative to GAPDH and β-actin. Protein abundance values were 
expressed relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. The 
enzyme activity was represented as CYP-specific product formation/min/mg protein. All 





Figure 4 (a-j): Correlation plots for mRNA and protein expression. Messenger RNA 
(mRNA) was expressed relative to β-actin. Protein abundance values were expressed 
relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. All values are 






Abstract graphic. Liver microsomes were prepared from human liver samples and 
trypsin-based digestion was carried out on samples after denaturation and alkylation. 
Furthermore, tryptic peptides were analyzed using LC-MS/MS in data dependent and 
SWATH-MS mode. The in-house spectral library was prepared from the using Protein Pilot 
and targeted data extraction for CYPs was performed in SWATH files using Skyline. Total 
intensity of CYPs in each batch was normalized using average intensity of β-galacotosidase 
for that batch. Subsequently, the relative protein abundance protein values were correlated 
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Supplementary information III: Quantification of hepatic CYP mRNA expression 
Total cellular RNA was isolated from the samples using RNeasy Mini Kit (QIAGEN Inc., 
Valencia, CA). The total RNA was reverse‐transcribed, and the single stranded DNA was 
used for real‐time PCR. The mRNA expression of hepatic CYP was quantified by real‐
time PCR using an Applied Biosystems 7500 Real‐Time PCR system (Applied 
Biosystems) at least two times according to the manufacturer’s instructions. The primers 
for CYP were shown in table below. 18S ribosomal RNA (rRNA) was also quantified as 
an internal control. 
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 Sequence Position Accession 
number 
Ref. 




GCTTCTACATCCCCAAGAAAT 1257-1277   
Reverse primer TCCCACTTGGCCAGGACT 1464-1447  Katoh et al., 
2004 CYP2A6   NM000762 
Forward 
primer 
AGCAACAGGCCTTTCAGTT 722-740   
Reverse primer CCCAATGAAGAGGTTCAAC 924-906   






1257-1278   
Reverse primer AGAGGCGGGGACACTGAATG
AC 
1539-1518  Katoh et al., 
2004 
CYP2C8   NM000770 
Forward 
primer 
AGATCAGAATTTTCTCACCC 665-684   
Reverse primer AACTTCGTGTAAGAGCAACA 822-803  Katoh et al., 
2004 CYP2C9   NM000771 
Forward 
primer 
CAGATCTGCAATAATTTTTCTC 665-686   
Reverse primer CTTTCAATAGTAAATTCAGAT
G 
882-861  Katoh et al., 
2004 





600-622   
Reverse primer GAGGGTTGTTGATGTCCATC 781-762  Katoh et al., 
2004 CYP2D6   NM000106 
Forward 
primer 
GGTGTGACCCATATGACATC 1207-1226   
Reverse primer CTCCCCGAGGCATGCACG 1428-1411   




GACTGTGGCCGACCTGTT 906-923   
Reverse primer ACTACGACTGTGCCCTTGG 1202-1184   





326-350   
Reverse primer CTTTTCATAAATCCCACTGGA
CCA 
454-431   
CYP3A5   NM000777 Busi et al., 2005 
Forward 
primer 
CCCACACCTCTGCCTTTG 223-240   
Reverse primer CAGGGAGTTGACCTTCATACG 343-323  Jigorel et al., 
2006 18S rRNA   NM003286 
Forward 
primer 
CGCCGCTAGAGGTGAAATTC 948-967   




Supplementary information IV: Enzyme assay conditions as provided by Seksui 
Xenotech LLC, Kansas City, MO 
 
Enzymatic assay conditions 
 
• HLM protein concentration: 50 µg/mL  
• Incubation temp: 37°C  
• Reaction time: 10 min 
 
• Potassium phosphate buffer (50 mM, pH 7.4) containing 3.0 mM MgCl2, EDTA 
(1.0 mM), NADP (1.0 mM), glucose-6-phosphate (5.0 mM), glucose-6-phosphate 
dehydrogenase (1 Unit/mL) 
 
• Probe substrates were incubated at a final concentration mentioned in the table below. 
 
 
 Probe substrate Probe reaction Substrate 
conc. (µM) 
CYP1A2 Phenacetin Phenacetin O-alkylation 80 
CYP2A6 Coumarin Coumarin 7-hydroxylation 50 
CYP3A4/3A5 Midazolam Midazolam 1-
hydroxylation 
30 
CYP3A4/3A5 Testosterone Testosterone 6β-
hydroxylation 
250 
CYP2B6 Bupropion Bupropion hydroxylation 500 
CYP2C8 Amodiaquine Amodiaquine N-
dealkyation 
20 
CYP2C9 Diclofenac Dicofenace 4-
hydroxylation 
100 
CYP2C19 S-Mephenytoin S-Mephenytoin 4-
hydroxylation 
400 
CYP2D6 Dextromethorphan Dextromethorphan 6- 
hydroxylation 
80 




Reference: Pearce et al., Effects of freezing, thawing, and storing human liver 
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Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease in the 
Western population. We investigated the association of nonalcoholic fatty liver disease 
(NAFLD) and diabetes mellitus on CYP3A4 activity in human liver tissue from brain dead 
donors (N=74). Histopathologically graded livers were grouped into normal (n=24), 
nonalcoholic fatty liver (NAFL, n=26) and nonalcoholic steatohepatitis (NASH, n=24) 
categories.  The rate of conversion of midazolam to its 1-hydroxy metabolite was used to 
assess in vitro CYP3A4 activity in human liver microsomes (HLM).  A proteomics 
approach was utilized to quantify the protein expression of CYP3A4 and related enzymes. 
Moreover, a physiologically based pharmacokinetic (PBPK) model was developed to allow 
prediction of midazolam concentration in NAFL and NASH patients. CYP3A4 activity in 
NAFL and NASH was 1.9 and 3.1-fold (p<0.05) lower than normal donors, respectively.  
Intrinsic clearance (CLint) was 2.7 (p<0.05) and 4.1 (p<0.01) fold lower in donors with 
NAFL and NASH, respectively.  CYP3A4 protein expression was significantly lower in 
NAFL and NASH donors (p<0.05) and accounted for midazolam hydroxylation variability 
in a multiple linear regression analysis (β=0.869, r2=0.762, P<0.01).  Diabetes was also 
associated with decreased CYP3A4 activity and protein. Both midazolam CLint and 
CYP3A4 protein abundance decreased significantly with increase in hepatic fat 
accumulation. Age and gender did not exhibit any significant association with the observed 
alterations. Predicted midazolam exposure was 1.7 and 2.3-fold higher for NAFL and 
NASH, respectively, which may result in a longer period of sedation in these patients. Data 




activity. Thus, further evaluation of clinical consequences of these findings on the efficacy 
and safety of CYP3A4 substrates is warranted. 
Keywords:  
CYP3A4, diabetes, drug metabolism, midazolam, nonalcoholic fatty liver disease, 



















The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising at an alarming 
rate in populations with diabetes and obesity.   The clinical diagnosis of NAFLD is based 
on limited or no consumption of alcohol, evidence of hepatic steatosis based on either 
biopsy or imaging, and the exclusion of other causes of liver disease.  NAFLD is sub-
categorized histopathologically as non-alcoholic fatty liver (NAFL), which is characterized 
by lipid accumulation in hepatocytes, or non-alcoholic steatohepatitis (NASH), which is 
associated with hepatic steatosis with inflammation and ongoing inflammatory or 
degenerative injury to hepatocytes 1, 2. Significant lobular inflammation, hepatic fibrosis, 
and hepatocyte necrosis present in NASH can progress to life-threatening liver cirrhosis 
and hepatocellular carcinoma (HCC).3 
Over 64 million people in the United States are projected to have NAFLD, with an 
estimated economic burden of about $103 billion, and these costs are highest among 
patients aged 45-65 year.4 Presence of NAFLD is highly correlated with insulin resistance 
and diabetes.5  Diabetes and NAFLD share common underlying pathophysiological 
processes including insulin resistance, hyperglycemia, dyslipidemia, inflammation and 
other cardiovascular conditions.6  A retrospective analysis of the hospital admission of 
patients with type 2 diabetes showed that the relative risk of NAFLD among these patients 
was 3-times higher in men and 5-times higher in women than those without diabetes.7 
Despite the widespread prevalence of NAFLD, no specific pharmacological 
therapies are available for its treatment; however, management of associated conditions 
including obesity, diabetes, and hyperlipidemia are often achieved pharmacologically or 




for these comorbidities.11 Moreover, CYP3A enzymes are also responsible for the 
metabolism of 30-50% of all drugs available in the market.11, 12 CYP3A4 and CYP3A5 
proteins of this superfamily of enzymes are expressed in human liver as well as 
extrahepatic tissues including intestine.13  Moreover, CYP3A4 plays a significant role in 
the catabolism of carcinogens (aflatoxin B1), and various endogenous steroids 
(progesterone, testosterone, cortisol and bile acids).14-17 Additionally, the enzyme is 
involved in the biotransformation of cholesterol, and the plasma concentration of 
cholesterol 4β-hydroxy has been used as an endogenous marker of CYP3A4 activity.18 
CAR, PXR, HNFα, and PPARα are some of the transcription factors which has been 
reported to modulate the expression of CYP3A4.19, 20 
A perturbation in CYP3A4 activity associated with diabetes, NAFLD or both is 
likely to alter the clearance of some drugs thereby changing the efficacy or safety of 
CYP3A substrates. Current studies in rodent models of the disease are conflicting as it has 
been widely known that most models fail to recapitulate the complex pathophysiology of 
human NAFLD fully.21-23  In rat models, reduced or elevated expression and activity of 
Cyp3a in steatosis and NASH has been reported 24-28. Similarly, studies in mice models are 
inconsistent, and results vary with diet and species 29-31. 
Genome-wide studies (GWAS) in human NAFLD patients found no significant 
changes in drug metabolism genes between normal and steatotic livers at mRNA 
expression level.32, 33 However, these results don’t capture the post-transcriptional and 
post-translational changes which may alter protein expression or activity.  The results of 
studies in human liver examining the impact of NAFLD on CYP3A4 activity are 




protein expression with severity of NAFLD, but no change in enzyme activity was 
observed. 34 However this study was done in a small sample size (steatosis =10, NASH=10) 
and no information on the ethnicity was provided. In contrast, Woolsey et al. found 
significantly lower activity CYP3A4 activity in human NASH subjects. 37 Diabetes was 
found to be associated with significant reduced CYP3A4 activity in human livers. 38  
However, the sample size in this study investigation was small, and presence of NAFL or 
NASH status was unknown.  
Therefore, using a large human liver tissue repository (N=74), well-characterized 
with respect to the presence of diabetes and NAFLD, we aimed to verify which disease 
condition influence the expression and activity of CYP3A4. The goal of studies using 
microsomes it to determine the intrinsic clearance and in vitro in vivo extrapolation 
(IVIVE). CYP3A4 functional activity and intrinsic clearance of midazolam was evaluated 
in HLM. As protein expression is an important factor for IVIVE, we determined the 
expression of CYP3A4 and related proteins in HLM using mass spectrometry.  
Furthermore, we developed a physiologically based pharmacokinetic (PBPK) model and 











Materials and reagents. Midazolam (MDZ), 1-hydroxy midazolam (1′-OH MDZ), and 1-
hydroxy midazolam-D4 (1′-OH MDZ-D4) were purchased from Cerilliant Corporation 
(Round Rock, TX). MS-grade formic acid, acetonitrile, and methanol were obtained from 
ThermoFisher Scientific (Waltham, MA). NADPH tetrasodium salt was from Calbiochem 
(EMD Millipore, Billerica, MA). OxiSelect TBARS assay kit (Malondialdehyde 
quantification) was purchased from Cell Biolabs, Inc., San Diego, CA and Amplex® Red 
Cholesterol Assay Kit was from ThermoFisher Scientific, Waltham MA. All other reagents 
and solvents used in the study were of analytical grade. 
 
Human liver bank. A novel human liver tissue repository (N=106) was created in our 
laboratory from hepatic tissue purchased from Sekisui XenoTech LLC (Kansas City, KS).  
The identity of donors was not known thereby the study was designated as Institutional 
Review Board (IRB) exempt category 4.  Age, gender, ethnicity, the cause of death, cold 
ischemia time, liver and body weight was available for ≥95% of the samples.  While being 
accessible, smoking and alcohol consumption was not assessed for effect on CYP3A4 
activity due to reasons discussed later in the text. Detailed donor demographics are given 
in Table 1.  The primary objective of the work was to study the effect of NAFLD and 
diabetes on CYP3A4 activity and protein levels. Therefore, only samples that were 
homozygous for CYP3A5*3/*3 (n=74) were included in this study. The results and findings 
of this study are thus limited to Caucasian male and female population.  Moreover, five 





Histological grading and study grouping.  Liver tissue was graded for steatosis, lobular 
inflammation, hepatocyte ballooning, and fibrosis by a physician specializing in 
histopathology (Suzanne Delamonte, MD).  The standardized scoring protocol assessed the 
presence and severity of hepatocellular steatosis, lobular inflammation, ballooning 
degeneration, and fibrosis.39 Formalin-fixed paraffin-embedded histological sections (5 
µm thick) of the liver, stained with hematoxylin and eosin dyes, were used to grade the 
severity of the disease. In brief, the slides were coded and scored concerning the abundance 
and distribution of hepatic steatosis, lobular inflammation, hepatocellular ballooning 
degeneration, and fibrosis. Steatosis was graded as 0 (<5%), 1 (5-33%), 2 (34-66%), or 3 
(>66%), reflecting the cross-sectional areas of the section showing hepatocytes with 
steatosis. Lobular inflammation was graded as 0 (absent), 1 (<2 foci/200x microscopic 
field), 2 (between 2 and 4 foci/200x microscopic field), or 3 (>4 foci/200x microscopic 
field).  Hepatocyte ballooning degeneration was graded as 0 (absent), 1 (rare, scattered 
cells) or 2 (readily detected). Fibrosis grading was simplified relative to the original report 
and graded as 0 (absent), 1 (mild and delicate in the perisinusoidal regions), 2 
(conspicuously present in perisinusoidal and periportal regions), 3 (bridging fibrosis), or 4 
(cirrhosis, which requires bridging fibrosis and regenerative nodules). The final scores 
represent the summed sub-scores. Steatosis was confirmed by Oil Red O staining of 
cryostat sections (10 microns) of the same liver samples, and fibrosis was confirmed by 
Sirius red staining of adjacent formalin fixed paraffin-embedded tissue sections.40  A 
composite of different histological sections of representative liver samples from different 




Subsequently, livers were categorized as normal, NAFL, and NASH based on the 
scoring algorithm described in supplemental figure I.41 Detailed histological 
characteristics of donors are given in supplemental table I. 
 
Malondialdehyde and cholesterol estimation. Quantification of malondialdehyde 
(MDA) in donor liver homogenate was determined using OxiSelect TBARS assay kit 
according to manufacturer instructions (Cell Biolabs, Inc., San Diego, CA). Total liver 
cholesterol was estimated using Amplex® Red cholesterol assay kit according to 
manufacturer’s instruction (ThermoFisher Scientific, Waltham, MA).  
 
Quantification of mRNA. Total RNA from liver tissues was isolated using the RNeasy 
mini kit (Qiagen Inc., Valencia, CA). Subsequently, the total cellular RNA was reverse-
transcribed, and the cDNA was used for real-time PCR analysis. The mRNA expression of 
hepatic CYP3A4 and the relevant transcription factors were quantified by real-time PCR 
using SYBR Green Master Mix on 7500 Real‐Time PCR system (Applied Biosystems, 
ThermoFisher Scientific, MA).  Human 18S ribosomal RNA (rRNA) was used as an 
internal control for relative expression of data. The information on PCR primers used is 
available in supplemental table II.  
 
CYP3A4 activity assay. Microsomes were prepared from liver samples as described 
previously in detail.42  CYP3A4 activity was assessed by formation of 1-hydroxy 
midazolam in HLM using midazolam as probe substrate.43 Enzymatic incubations were 




Microsomal protein concentration used was 50 µg/mL and concentrations of midazolam 
were 0, 0.2, 1, 2.5, 5, 10, 25 µM. The addition of NADPH initiated the reaction, and the 
incubations were carried out in a shaking water bath (75 rpm) kept at 37°C. After 20 min, 
the reaction was terminated by addition of ice-cold acetonitrile containing 0.5% formic 
acid and internal standard (1-hydroxymidazolam-D4, 50 ng/mL). Subsequently, samples 
were centrifuged at 2000 g for 5 min at 4°C. The supernatant was collected, and 5 µL was 
injected for quantification of 1-hydroxy midazolam using the UPLC-MS method described 
below. CYP3A4 activity (Vmax; maximum rate of reaction) was expressed as pmol/mg 
microsomal protein.  
 
Quantification of 1-hydroxy midazolam. Samples were analyzed using a previously 
published method with some modifications to chromatography method as described below 
43. Chromatographic separation was performed using a gradient elution mode using 10 mM 
ammonium acetate and 10% methanol (A) and acetonitrile (B) at the flow rate of 400 
µL/min. The linear gradient started with 25% B until 0.5 min, 60% B at 1.5 min, 90% B at 
3 min before returning to 25% B at 4 min. All other mass spectrometer parameters were 
same as previously described.43 
 
Quantification of proteins using mass spectrometry. Protein levels of CYP3A4, 
NADPH-cytochrome P450 reductase (CPR), and Cytochrome b5 (Cyb5) in human liver 
microsomes were determined using mass spectrometry and “Total Protein Approach”.44 
Microsomal fractions were digested with trypsin and analyzed in Data-Dependent 




Concord, CA). The raw data files from one of our previous study were analyzed using 
MaxQuant (ver 1.5.2.10).42 The specifics of protein digestion and mass spectrometry 
analysis were previously described in the literature.42, 44 The proteins were searched on 
Andromeda search engine against UniProt human protein database (updated Oct 2016) at 
1% false discovery rate (FDR).45 Cysteine carbamidomethylation was selected as fixed 
modifications for the search. Label-free quantification (LFQ) was performed with a ratio 
count of 1 and maximum of two missed cleavages were allowed. All the other MaxQuant 
settings were kept as default values. The absolute protein levels were calculated using 
“Total Protein Approach” from LFQ intensities obtained from MaxQuant using the 
equations given below44.  





𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝) =
𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑝)
𝑇𝑜𝑡𝑎𝑙 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 𝑥 𝑀𝑊(𝑝) 
 [mol/gram total protein] 
where MS signal (p) refers to total LFQ signal intensity for CYP3A4, CPR or Cyb5. Total 
MS signal refers to the total LFQ intensity of all the proteins and MW represents the 
molecular weight of respective protein.   
 
Modeling of enzyme kinetics data. In vitro CYP3A4 kinetics data were fitted using 
Prism® version 6 (GraphPad Software Inc., La Jolla, CA) into a nonlinear least-squares 
regression equation given below 46. 
𝑣 =
𝑉𝑚𝑎𝑥 × 𝑆








Where S represents the concentration of substrate, v is the velocity of 1-OH midazolam 
formation; Km is Michaelis-Menten constant (substrate concentration required for an 
enzyme to reach one-half its maximum velocity), and Ks is inhibition constant. Vmax 
(maximum rate of product formation) and Km were estimated from the equation, and 
apparent in vitro intrinsic clearance (CLint, app) was calculated as Vmax/Km.  Intrinsic 
clearance for whole liver (CLint, whole liver) was calculated using the equations given 
below and was expressed as L/min. MPPGL denotes the yield of membrane proteins per 
gram of liver.  
𝐶𝐿𝑖𝑛𝑡 (𝑤ℎ𝑜𝑙𝑒 𝑙𝑖𝑣𝑒𝑟) = 𝐶𝐿𝑖𝑛𝑡, 𝑎𝑝𝑝 ×  𝑀𝑃𝑃𝐺𝐿 × 𝐿𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡   
SimCYP based PBPK simulation. A physiologically based pharmacokinetic (PBPK) 
model was developed in SimCYP population-based simulator (ver 15, Certara LP, 
Sheffield, UK) using CYP3A4 protein and midazolam enzyme kinetic parameters.  A 
virtual Caucasian population (Sim-NEurcaucasian) with an equal proportion of males and 
females, 20-65 year old, was selected for simulations.  A minimal PBPK model was utilized 
for estimating plasma concentration-time profiles. Portal and arterial blood flow were the 
same for all the populations given a lack of data on hepatic blood flows in NAFL and 
NASH. An intravenous bolus dose of 5 mg midazolam was given, and default SimCYP 
compound file was used. In vitro Vmax and Km values were substituted for a respective 
study group in the “whole organ metabolic clearance” tab implemented in SimCYP. 
Default CYP3A4 phenotype values for the Caucasian population was replaced with protein 
concentrations determined in this study. Five virtual trials with 50 subjects per study were 
used for prediction of systemic midazolam concentration. All other parameters were kept 




Statistical analysis. Statistical analysis was performed with SPSS version 24 (IBM 
Analytics, Armonk, NY), and Prism® version 6 (GraphPad Software Inc., La Jolla, CA) 
was used for graphs, Vmax and Km calculations. Descriptive statistical values in tables are 
reported as mean ± standard error (SE) unless otherwise stated. Mann-Whitney U test (2-
tailed) was used to compare the effect of gender. Non-parametric Kruskal-Wallis test (2-
tailed) without multiple corrections was used when studying three or more groups.  The 
correlation was analyzed using nonparametric Spearman correlation analysis. Linear and 
multiple regression analysis were used to determine the contribution of predictors toward 
explaining variability in CYP3A4 activity. P <0.05 was considered significant for all the 















CYP3A4 activity and protein expression are decreased in NAFLD. Significantly lower 
CYP3A4 activity (Vmax expressed as pmol/min/mg protein) was observed in microsomes 
from NAFLD donors (Fig. 2).  HLM from NASH donors exhibited 3.1-fold lower 
midazolam Vmax as compared with normal donors (Table 2).  Midazolam Vmax was 1.9-
fold lower in HLM from NAFL donors, but the effect was not statistically significant 
(P>0.05). CLint (L/min) was significantly lower intrinsic clearance in NAFL (2.7±0.9, 
P<0.05) and NASH (1.8±0.6, P<0.01) as compared to normal (7.3±1.8, Fig. 3). Michaelis-
Menten constant (Km) was comparable in different study groups and ranged from 1.6 to 2.3 
µM (Table 2).  
Mean protein levels of CYP3A4 decreased with progression of disease (P<0.05, 
Fig. 3). CPR and Cyb5 protein levels were significantly lower (P<0.05) in HLM from 
NAFLD donors (Table 3). The progression of disease from NAFL to NASH reduced the 
CYP3A4 mRNA expression (Fig. 4). However, the decrease was not significant. The levels 
of transcription factors, PXR, CAR, HNF4α and PPARα mRNA, decreased with disease 
progression (Fig. 4). The reduction in CAR mRNA level was significantly different 
between normal and NASH donors (P<0.05). 
 
CYP3A4 activity and protein expression are decreased in diabetes and NAFLD. Given 
the high prevalence of NAFLD in patients with diabetes, we further studied the combined 
effect of the insulin resistance and fatty liver on CYP3A4 protein and activity. The levels 
of CYP3A4 activity, protein and mRNA expression and relevant transcription factors are 




statistically significant in HLM from diabetic donors. For non-diabetic donors, the study 
parameters showed a trend of reduction in disease state but were not statistically significant 
except CPR. In contrast, CYP3A4 activity and Clint was significantly lower in HLM from 
diabetic NAFL and NASH donors. Similarly, a significant decrease in CYP3A4, CPR, and 
Cyb5 was also observed in diabetic donors with NAFLD. Interestingly, while mRNA 
expression decreased in both disease states, the mean differences failed to achieve 
statistical significance. 
 
CYP3A4 activity and protein expression decrease with increase in liver fat. The impact 
of varying grades of steatosis on CYP3A4 activity, protein and mRNA levels was also 
evaluated. When the donors were categorized based on the severity of steatosis, a 
significant reduction in CLint was observed (Fig. 5). CYP3A4 activity decreased with 
increase in liver fat content, but the decline was not significant due to extensive variability. 
CYP3A4, CPR, and Cyb5 protein levels also reduced with an increase in the severity of 
steatosis (Fig. 5, supplemental figure III). 
 
Effect of age. The average age of normal donors was similar in NAFL and NASH donors 
(Table 1).  Donor age showed no significant correlation with CYP3A4 activity (r=-0.143, 
P >0.1), CYP3A4 protein (r=-0.101, P >0.1), and CLint (r=-0.228, P >0.1, Supplemental 
figure IV). The association with age was also insignificant for CYP3A4 mRNA.  
 
Effect of gender. Almost equal number of male and female donors were included in this 




marginally higher CYP3A4 activity, CLint, protein and mRNA levels than female donors. 
However, no significant association (P>0.1) was observed between gender and CYP3A4 
activity, Clint as well as CYP3A4, CPR and Cyb5 protein abundance. The relationship 
between gender and CYP3A4 and related proteins was also examined, and no significant 
correlations were found (Supplemental table III). 
 
Correlation between activity, mRNA and protein levels. The rate of 1-
hydroxymidazolam formation showed a significantly positive correlation with CYP3A4 
protein and mRNA levels. Similarly, CYP3A4 protein and mRNA expression levels 
exhibited significant positive correlation (supplemental figure V). A significant but 
moderate correlation was found between CPR protein and CYP3A4 activity (r=0.446, P 
<0.01), and CYP3A4 protein (r=0.547, P <0.01). The correlation between Cyb5 protein 
and CYP3A4 activity (r=0.463, P <0.01), and CYP3A4 protein (r=0.592, P <0.01) was 
moderate and significant. The association between two CPR and Cyb5 was significant as 
well (r=0.607, P <0.01). Correlation plots can be found in supplemental figure V. 
 
Linear regression analysis of protein and activity. Univariate linear regression analysis 
was used to determine how much of the variability in CYP3A4 activity was accounted by 
CYP3A4, CPR, and Cyb5 protein levels. We found that CYP3A4 (r2=0.761, P<0.01), CPR 
(r2=0.331, P<0.01) and Cyb5 (r2=0.197, P<0.01) protein levels were significant predictors 
of the CYP3A4 activity in HLM.  However, multiple linear regression analysis returned a 
regression coefficient (r2=0.762, P<0.01) which was marginally better than the coefficient 




Standardized beta coefficients of multiple regression models for CYP3A4 protein 
(β=0.869, P<0.01) explained most of the variability in midazolam hydroxylation activity, 
whereas CPR protein (β =0.062, P>0.1) and Cyb5 protein (β =-0.069, P>0.1) revealed the 
minimal contribution of each predictor to the model. 
 
SimCYP based PBPK model. The simulated plasma profile of midazolam was in good 
agreement with the observed profiles previously reported in the literature so as the values 
of area under the concentration-time curve (AUC0-24), maximum midazolam 
concentration (Cmax) and clearance (CL).47  A 1.8 and 2.3-fold increase in exposure (based 
on AUC) was found for NAFL and NASH populations, respectively (supplemental table 
IV). Predicted plasma concentration of midazolam in a Caucasian population with 
CYP3A4 phenotype and enzyme kinetic parameters is shown in Fig. 6.  . The predicted 
intravenous clearance (CL) of midazolam in normal, NAFL and NASH group was 16.6, 
9.4 and 8.6 L/h, respectively (supplemental table IV). The pharmacokinetic parameters 
when accounting for insulin resistance (diabetes) and fatty liver (NAFLD) are given in 












Our studies suggest downregulation of CYP3A4 protein and activity in NAFLD. While 
some findings were not statistically significant for NAFL, a trend of reduction was 
observed.  This pattern achieved significance for HLM from NASH donors suggesting that 
the decrease in CYP3A4 activity and CYP3A4 protein continues with the severity of 
disease as it progresses from benign stage to NAFL and NASH. We also found that insulin 
resistance along with steatosis appears to provide a double-blow leading to decreased 
CYP3A4 protein and activity. Similar substrate affinity (Km) among the groups indicate 
that the differences seen in the velocity of the reaction (1-hydroxy midazolam formation) 
were in fact due to an altered enzyme level rather than its affinity for the substrate. Multiple 
linear regression modeling showed that the variability in midazolam hydroxylation was 
accounted mainly by CYP3A4 protein in HLM. SimCYP based PBPK model was in good 
agreement for the healthy population when in vitro parameters from this study were used.   
Woolsey and colleagues found that midazolam concentrations in human subjects 
with NASH were significantly higher as compared to control subjects (indicating reduced 
CYP3A activity).37 Fisher and colleagues suggested a decrease in CYP3A4 expression and 
functional activity with the progression of NAFLD, but this difference was not statistically 
significant.34 The same study reported that the mRNA expression was not different between 
NAFLD groups. We found that the mRNA expression of CYP3A4 and its transcription 
factors (CAR, PXR, HNF4α, and PPARα) was reduced in livers from NAFLD donors, but 
the effect was statistically insignificant except for CAR mRNA.  In contrast, the level of 




involvement of transcriptional and translational mechanisms in down-regulation of 
CYP3A4 activity.  
Two primary inducible nuclear transcription regulators of CYP3A4 mRNA 
expression in human, PXR and CAR, are widely affected by dietary, genetic, 
environmental and pathological factors.48 Similar PXR mRNA levels between fatty and 
normal human liver microsomes were previously reported.35 HNF4α was identified as a 
critical constitutive regulator of PXR and CAR-mediated transcriptional induction of 
CYP3A4.49 Conversely, we found a decrease in HNF4α levels, but the alteration was 
statistically insignificant between the three groups. Interestingly, a study on PXR-knockout 
rat model indicated that down-regulation of hepatic CYP450s via a PXR-independent 
mechanism.50  It could partially explain why the PXR mRNA levels were not significantly 
different in our study despite a discernible decrease in the disease state. Recently, Woolsey 
et al. reported that CYP3A4 down-regulation might be due induced fibroblast growth factor 
21 (FGF21) leading to reduced PXR localization and binding to the CYP3A4 proximal 
promoter.51 While some have reported elevated CAR in the pathogenesis of NASH in mice, 
other studies suggest a downregulation of CAR.52, 53 We also found that CAR mRNA 
expressed was decreased with progression of NAFLD.  PPARα governs transport and β-
oxidation of fatty acid in the liver in addition to regulation of inflammatory response. We 
found different levels of PPARα in our groups, but the effect was insignificant. Due to lack 
of data, we speculate that tandem decrease in levels of transcription factors may result in 
significant downregulation of some target proteins. 
Diabetes and insulin resistance are associated with NAFLD with up to 70% patients 




of diabetes on CYP3A4 expression and activity in human liver, but the impact of NAFLD 
was not studied.38 In this study, we found that while there was a decrease in CYP3A4 
activity and protein, the effect was statistically insignificant in HLM from non-diabetic 
donors. In contrast, NAFL and NASH donors with diabetes showed a statistically 
significant decrease in activity, protein expression, and midazolam clearance. Interestingly, 
we found that diabetic, normal donors exhibited marginally higher CYP3A4 activity and 
Clint as compared to non-diabetic normal donors. We speculate that this anomaly could be 
possibly attributed to pharmacological agents that these diabetic donors might be receiving. 
Our lab is currently pursuing a challenging project to find out the exposure to different 
drugs at the time of death in our liver bank.  Based on the data, we speculate that the 
heightened reduction of activity and midazolam Clint in diabetic subjects may be due to 
the double-punch which insulin resistance appears to trigger in steatotic livers. It is also 
supported in part by lack of statistically significant decrease in CYP3A4 activity in non-
diabetic livers.  
Kolwankar and colleagues found an independent association between hepatic 
steatosis and reduced CYP3A activity which decreased with the severity of steatosis.35 
Another study in human hepatocytes isolated from macrosteatosis livers found a significant 
reduction in CYP3A4 activity without any alteration in CPR levels in microsomes from 
steatotic and nonsteatotic livers.56 We also found that livers with >5% hepatic fat were 
associated with the low CYP3A4 activity and intrinsic clearance of midazolam in HLM.  
Previous studies have reported a higher amount of protein, mRNA and CYP3A4 
activity in female livers.13 In contrast, we found that males exhibited slightly higher 




CYP3A4 activity than men based on pharmacokinetic studies with cyclosporine, 
erythromycin, and midazolam.57, 58 Conversely, studies with cyclosporine and midazolam 
suggest an insignificant gender difference in metabolism of these drugs. As CYP3A4 and 
P-glycoprotein 1 (Pgp) share a large number of common substrates; increased metabolism 
in females may in part be due to lower Pgp activity in canalicular membrane rather than 
the CYP3A4 activity in the endoplasmic reticulum.59 Schuetz reported that Pgp in women 
was almost half the levels of that in men.60 Moreover, another study in HLM found that 
median CYP3A4 content was 2-fold higher in women than men with the 
CYP3A5*3/*3 livers (P<0.05).61  
Reports on the effect of NAFLD on NADPH-cytochrome P450 reductase (CPR) 
are lacking. The expression of CPR reduced significantly with progression of disease from 
NAFL to NASH. Multiple linear regression analysis with CYP3A activity as the dependent 
variable revealed that CPR protein content does not account for additional variability when 
CYP3A4 protein is present as a predictor variable. These results are in line with a previous 
report which found that CYP3A variability was independent of CPR protein level.62  
Oxidative stress has been found to be a critical factor associated independently with 
NAFLD.63, 64 We found that livers from NAFLD donors had higher malondialdehyde levels 
compared to normal donors suggesting increased oxidative stress (Table 1). Additionally, 
liver samples from NALFD donors exhibited a significantly higher amount of cholesterol 
as compared to normal donors (Table 1). Increased liver cholesterol leads to activation of 
Kupffer and stellate cells in the liver, thereby promoting inflammation and fibrogenesis.65 
Production of reactive oxygen species during NAFLD may lead to lipid peroxidation which 




Studies in the last decade have suggested a strong relationship between metabolic 
diseases like NAFLD and microRNA expression in human liver.68, 69 These miRs can 
regulate expression and mRNA stability function, in addition to the regulation of lipid 
metabolism, inflammation, and apoptosis.70, 71 Significantly, upregulated miR-155 levels 
in cirrhotic livers showed a strong negative correlation with CYP3A activity.72 Moreover, 
miR-27b was found to suppress the translation of CYP3A4 protein without affecting the 
mRNA levels of the enzyme.73 We speculate elevated miR species to be one of the factors 
responsible for a contrast of mRNA and protein expression levels in NAFLD. 
The information on any other underlying disease or drug use by donors at the time 
of their death was not available. The data on prior drug usage, alcohol consumption, and 
smoking can be challenging to interpret, and it is naïve to assume that such information 
provided by the vendor is accurate.74 Contrary to this, data on age and gender can be 
considered reliable. Therefore, we did not evaluate the effect of smoking and alcohol 
consumption on the CYP3A activity and clearance of midazolam.  
The performance of PBPK model in the normal population was used to estimate 
the accuracy of predictions made in the normal population.47 Compared to normal 
population, a 2.3 fold higher midazolam exposure was predicted by the model for NASH 
population (supplemental table IV), which is consistent with 2.4-fold higher systemic 
midazolam concentration reported in a clinical study with subjects with NASH.37 PBPK 
model also suggested prolonged sedation in NAFLD patients with compromised liver 
function. An average midazolam effective concentration (EC50) of 68.7 ng/mL (10.9-
165.0, 95% CI) for a Ramsay score between 3-5 was recently reported in a population-




NAFLD population showed that the midazolam concentration would remain over EC50 for 
extended time compared to the normal population (Fig. 6).  It was reported that subjects 
with alcoholic cirrhosis had a significantly higher elimination half-life of midazolam 
compared to healthy subjects.76 Indeed, Li et al. have reported that patients with the severe 
liver disease were more sensitive to midazolam and achieved loss of consciousness at much 
lower systemic concentration compared to subjects with normal hepatic function.77 
Therefore, we can speculate that NAFL and NASH patients may also be more sensitive to 
midazolam that non-NAFLD patients. 
Further studies with different probes and population cohorts are warranted to 
corroborate these findings and understand the underlying mechanism/s responsible for 
perturbations in CYP3A4 expression. A well-planned in vivo trial would be an ideal study 
to address the discrepancies in literature but has its limitations. For instance, obtaining a 
biopsy sample from healthy individuals remains an ethical challenge for researchers. Given 
these results are largely limited to Caucasian population, care should be taken for 
interpolation of the results. Efforts are currently underway in our lab to study different 
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Table 1: Overview of Caucasian donor demographics 
 
Normal NAFL NASH 
n (Male, Female) 24 (13, 11) 26 (10, 16) 24 (11, 13) 
Ethnicity# (n)  
C, AA, H 
24, 0, 0 26, 0, 0 22, 1, 1 
Age1 (years) 50.2±3.0 52.4± 2.1 53.1±2.1 
Body-mass index1 
(kg/m2) 
31.4±3.0 33.9±2.5 32.5±1.6 
Diabetes mellitus  
(no, yes) 
11, 13 14, 12 11, 13 
Liver weight1 (kg) 1.6±0.1 2.0±0.2 1.9±0.1 
Body weight1 (kg) 88.7±7.2 97.1±6.6 94.0±4.7 
Malondialdehyde 1 
(nmol/mg protein) 
0.7±0.1 1.2±0.2** 1.5±0.2** 
Cholesterol1 
(µg/mg liver) 
16.3±1.3 21.0±1.7* 22.6±1.9** 
CYP3A5*3/*3 (n) 24 26 24 
CYP3A4*22 (n) 
*1/*1, *1/*22 
23, 1 23, 3 23, 1 
CYP3A4*1B (n) 
*1/*1, *1/*1B 
24, 0 26, 0 23, 1 
 
#C-Caucasian, AA-Afro-American, H-Hispanic; 1All descriptive statistics values 
represent mean ± SE. *P < 0.05, **P < 0.01 as compared to normal. P-values reported 






Table 2: Effect of nonalcoholic fatty liver disease on midazolam hydroxylation 
parameters 
 Normal NAFL NASH 
Vmax 
(pmol/min/mg protein) 
553.8±134.9 281.2±80.9 176.2±40.4* 
Km (µM) 1.6±0.1 2.0±0.2 2.3±0.4 
CLint, whole liver 
(L/min) 
7.3±1.8 2.7±0.9* 1.8±0.6** 
 
All descriptive statistics values represent mean±SE. *P < 0.05, **P < 0.01 as compared 
to normal. P-values reported from non-parametric Kruskal-Wallis test (2-sided) without 






























Table 3: Effect of nonalcoholic fatty liver disease on protein abundance 
 Normal  NAFL NASH 
CYP3A4 
(pmol/mg protein) 
131.8±20.4 68.0±18.0* 59.9±7.3* 
CPR 
(pmol/mg protein) 
51.1±2.3 39.3±2.4** 36.6±1.9** 
Cyb5 
(pmol/mg protein) 
654.5±41.2 506.5±26.3* 515.3±24.6* 
 
All descriptive statistics values represent mean±SE. *P<0.05, **P < 0.01 as compared to 
normal. P-values reported from nonparametric Kruskal-Wallis test (2-sided) without 






Table 4: Effect of diabetes and NAFLD on CYP3A4 activity, protein and mRNA 





Table 4: Effect of diabetes and NAFLD on CYP3A4 activity, protein and mRNA 





Figure 1. Histological staining of liver sections. (A, D) normal controls, (B, E) patients 
with diabetes mellitus and hepatic steatosis, i.e. non-alcoholic fatty liver (NAFL), and (C, 
F) patients with diabetes mellitus and non-alcoholic fatty liver disease with inflammation, 
i.e. non-alcoholic steatohepatitis (NASH) were stained with (A-C) Hematoxylin and Eosin 
or (D-F) Sirius Red.  (A) Control livers exhibited uniform chord-like arrangements of 
hepatocytes, (A-Inset) homogeneous cytoplasm, and (D and D-inset) minimal delicate 
Sirius red staining of sinusoidal collagen. (B) In diabetes, NAFL was associated with (B, 
B-inset) macrovesicular (large vacuoles filling cytoplasm) and microvesicular (clusters of 
small cytoplasmic vacuoles) lipid droplets (clear circumscribed structures in cytoplasm) 
and (E, E-inset) predominantly delicate but focally moderate Sirius red labeling of 
sinusoidal and pericellular collagen. (C) In patients with diabetes and NASH, the livers 
showed abundant (C, C-inset) macrovesicular and microvesicular lipid vacuoles in 
hepatocytes, conspicuous lymphomononuclear inflammatory cell infiltrates among 
hepatocytes, and (F) prominent Sirus red staining of bridging fibrosis and (F-inset) peri-
hepatocyte collagen. (Original magnifications x625) 
Figure 2. Effect of nonalcoholic fatty liver disease on CYP3A4 activity. (A) CYP3A4 
activity, (B) CLint (whole liver). Column and error bars represent mean±SE. *P<0.05 as 
compared to normal. P-values reported from nonparametric Kruskal-Wallis test (2-sided) 
without adjustment for multiple comparisons. 
Figure 3. Effect of nonalcoholic fatty liver disease on protein expression. (A) CYP3A4, 




represent mean±SE. *P<0.05 as compared to normal. P-values reported from 
nonparametric Kruskal-Wallis test (2-sided) without adjustment for multiple comparisons. 
Figure 4. Effect of nonalcoholic fatty liver disease on relative mRNA expression. (A) 
CYP3A4 mRNA, (B) CAR mRNA, (C) PXR mRNA and (D) HNF4α mRNA. Column and 
error bars represent mean±SE. *P<0.05 as compared to normal. P-values reported from 
nonparametric Kruskal-Wallis test (2-sided) without adjustment for multiple comparisons. 
Messenger RNA data expressed relative to 18S rRNA 
Figure 5. Effect of different grades of steatosis. (A) CYP3A4 activity, (B) CLint (whole 
liver), (C) CYP3A4 protein. Column and error bars represent mean±SE. *P<0.05 as 
compared to <5% liver fat. P-values reported from nonparametric Kruskal-Wallis test (2-
sided) without adjustment for multiple comparisons. 
Figure 6. SimCYP predicted plasma concentration of midazolam in virtual Caucasian 
population indicating a higher concentration and longer sedation time with respect to 
disease state (A) in a virtual population of normal, NAFL or NASH patients irrespective 
of diabetes status (B) without diabetes normal versus NAFL or NASH (C) with diabetes 

















































































Supplemental table files 
Supplemental table 1: Histological characteristics of the donors. 
Supplemental table II: PCR primers used in the study. 
Supplemental table III: Effect of gender on CYP3A4 activity, protein and mRNA 
expression.  
Supplemental table IV: Predicted pharmacokinetic parameters (Geometric mean, 95% 
CI) after 5 mg intravenous dose in populations accounting for fatty liver. 
Supplemental table V: Predicted pharmacokinetic parameters (Geometric mean, 95% CI) 
after 5 mg intravenous dose in populations accounting for fatty liver and insulin resistance. 
 
Supplemental figure files 
Supplemental figure I. Scheme of the histological scoring system used for group 
formation in the study. 
Supplemental figure II. Correlation of CYP3A4 activity with (A) CYP3A4 mRNA and 
(B) CYP3A4 protein. (C) Correlation between CYP3A4 mRNA and protein expression. 
P<0.05 were considered significant. Correlation coefficient represents Spearman r. 
Messenger RNA data expressed relative to 18S rRNA. Some parameters were log10 
transformed for graphical representation. 
Supplemental figure III. Effect of different grades of steatosis (A) NADPH cytochrome 




mean ± SE. *P<0.05 as compared to <5% liver fat. *P-values reported from nonparametric 
Kruskal-Wallis test (2-sided) without adjustment for multiple comparisons. 
Supplemental figure IV: Spearman correlation analysis of age with (A) CYP3A4 activity 
(pmol/min/mg protein), (B) CLint (L/min), (C) CYP3A4 protein (pmol/mg protein) and 
(D) CYP3A4 mRNA. P<0.05 was considered significant. Correlation coefficient 
represents Spearman r. Messenger RNA data expressed relative to 18S rRNA. Closed 
circles represent normal, open circles represent NAFL and triangles represent NASH 
samples. 
Supplemental figure V. Association of NADPH-cytochrome P450 reductase with (A) 
CYP3A4 activity (pmol/min/mg protein) and (B) CYP3A4 protein (pmol/mg protein). 
Correlation of cytochrome b5 with (C) CYP3A4 activity (pmol/min/mg protein) and (D) 
CYP3A4 protein (pmol/mg protein). (E) Correlation between NADPH-cytochrome P450 
reductase and cytochrome b5 proteins.  P<0.05 was considered significant. Correlation 
coefficient represents Spearman r. Messenger RNA data expressed relative to 18S rRNA. 














 Supplemental table 1: Histological characteristics of donors 
Histological score  Normal NAFL NASH 
  n=24 n=26 n=24 
Steatosis     
0  24 0 0 
1  0 12 7 
2  0 7 7 
3  0 7 10 
Hepatocyte 
ballooning 
    
0  23 19 0 
1  1 6 18 
2  0 1 6 
Lobular 
inflammation 
    
0  9 9 0 
1  12 13 18 
2  3 4 6 
Fibrosis     
0  12 10 8 
1  9 11 12 
2  2 4 3 
3  1 1 1 
Diabetic   11 14 11 































Supplemental table III: Effect of gender on activity, protein and mRNA 
expression 
Gender Female Male 




Km (µM) 1.96±0.18 1.96±0.25 















CAR mRNA1 1.94±0.24 2.76±0.73 
PXR mRNA1 1.98±0.25 1.87±0.24 
HNF4α mRNA1 1.81±0.31 1.56±0.24 
PPARα mRNA1 1.33±0.20 1.21±0.24 
 
All descriptive statistics value represent mean±SE. *P<0.05 as compared to normal liver. 
P-values reported from non-parametric Mann-Whitney U test (2-sided). 1Messenger RNA 




















Supplemental table IV: Predicted pharmacokinetic parameters (Geometric 
mean, 95% CI) after 5 mg intravenous dose in virtual populations (n=250 in 
each group) accounting for fatty liver.  
 Normal NAFL NASH 
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Differential basal expression of drug disposition proteins (DDP) in the disease state can 
contribute to significant changes in systemic exposure to xenobiotics. The changes in 
abundance of drug-metabolizing enzymes (DME) is vital for accurate in vivo extrapolation 
and prediction of hepatic clearance from in vitro data. To gain insight into the alterations 
of phase-I and phase-II DDPs during non-alcoholic fatty liver disease (NAFLD), we 
compared the protein abundance and activity in 106 human liver samples (control=42, 
nonalcoholic fatty liver; NAFL=34 and nonalcoholic steatohepatitis; NASH=30). In-
solution trypsin digestion of proteins in whole tissue lysate was carried out using pressure-
cycling technology. Data were acquired in data-dependent acquisition (DDA) mode on a 
triple-time of flight (TOF) mass spectrometer, and absolute protein levels were determined 
using total protein approach. Functional activity data from the tissue vendor were used to 
evaluate the effect of disease on activity and further correlated with protein abundance. 
CYP1A2 and CYP3A4/5 protein abundance and activity were downregulated in the 
NAFLD whereas minor changes were observed for other CYPs. UGT and SULT-
regulation were mostly similar between the different groups except for SULT1A1 and 
SULT1A2. Mitochondrial proteins (ACADSB, ACSM3/5) involved in lipid metabolism 
were also dysregulated in NAFLD. Levels of CPS1 were significantly lower in the disease 
state. Here, we provide a quantitative protein abundance data which would allow 







Human liver, facilitated by several drug metabolizing enzymes (DMEs) and 
transporters, is the primary organ responsible for the elimination of xenobiotics and 
endogenous compounds. Nonalcoholic fatty liver disease (NAFLD), a chronic liver 
condition is defined as the presence of >5% of macrovascular steatosis in individuals 
without high alcohol intake (<20 g per day for women, <30 g per day for men) and ranges 
from the benign fatty liver to severe nonalcoholic steatosis (NASH) (Vuppalanchi and 
Chalasani, 2009). A recent meta-analytic report estimated higher prevalence in the Middle 
East and South America with a global NAFLD prevalence of 25.24% (95%CI 22.1-28.7) 
(Younossi et al., 2016b). The prevalence of NAFLD in the United States was found to be 
30% with 10.3% of patients with advanced fibrosis (Le et al., 2017). In the USA, NAFLD 
is also associated with significant economic (~$103 billion) and clinical burden (~64 
million people projected to have NAFLD) (Younossi et al., 2016a).  NAFLD is commonly 
associated with hepatic fat accumulation, lipotoxicity, insulin resistance, obesity and 
cardiovascular diseases (Brunt and Tiniakos, 2010). The disease is characterized by the 
presence of significant hepatic steatosis in patients without the considerable intake of 
alcohol (Chalasani et al., 2012)., NAFLD is associated with the histopathological features 
including steatosis, hepatocyte ballooning and lobular inflammation (Younossi and Henry, 
2016). Recent studies have shown significant dysregulation of hepatic DMEs in S9 
fractions from cirrhotic liver samples (Prasad et al., 2017). NAFLD was associated with 
substantial downregulation of CYP3A4 protein and activity in liver from CYP3A5*3/*3 
expressers (Jamwal et al., 2018). However, the information on the expression of other 




Akhlaghi, 2017). The current literature suggests alteration in hepatic cytochrome P450 
(CYP) expression, activity or both, however, the directionality of change lacks agreement 
(Niemela et al., 2000; Kolwankar et al., 2007; Fisher et al., 2009; Woolsey et al., 2015). 
One potential explanation for such a wide discrepancy in literature can be attributed to the 
interindividual variability, and sample size used to derive the inferences. Misuse of 
classification systems and incorrect characterization of study samples may have also lead 
to different conclusions (Brunt et al., 2011). 
The last decade has seen a rise in the use of mass spectrometry (MS) based 
techniques for quantification of the protein expression (Prasad and Unadkat, 2014; Fallon 
et al., 2016). Despite being the gold standard, targeted methods of protein quantification 
are costly and need significant time for optimization of mass spectrometer conditions. 
Label-free quantification (LFQ) has emerged recently as an alternative approach for 
comparative analysis of protein expression across different samples (Wong and Cagney, 
2010). Accurate and robust quantification with LFQ approaches is complex, and different 
strategies for extracting quantitative data has been developed (Wong and Cagney, 2010). 
A comprehensive cost comparison of different mass spectrometry-based techniques 
reported significant cost savings with label-free based quantitative proteomics (Al Feteisi 
et al., 2015).   
Disease conditions have been known to impact the abundance of drug disposition 
proteins (DDPs) in the liver, hence leading to altered drug profiles and often to side-effects 
(Gandhi et al., 2012; Dietrich et al., 2017; Evers et al., 2018). However, it is not always 
practical to measure the impact of hepatic impairment on clinical outcomes in special 




pharmacokinetic and drug metabolism in populations are gaining popularity for 
populations which represent clinical challenges (Sager et al., 2015; Jamei, 2016). The 
patients with metabolic syndrome are often on multiple medications and alterations in 
expression of DMEs carries a potential of significant drug-drug interactions (DDI). PBPK 
models can be used in such cases to predict DDI once representative clinical parameters 
are available (Marsousi et al., 2017). Along with physicochemical properties of a drug, 
physiological information is vital for accurate prediction of drug exposure. Quantification 
of DDPs is therefore important for development of simulation models. Due to the lack of 
clinical studies in NAFLD patients, PBPK models should be qualified for the normal 
population before using them for prediction in special population groups (Shebley et al., 
2018). Availability of clinical study data in the future would help to validate these models. 
Traditionally, the expression and activity of DMEs have been measured in a human 
liver microsomal fraction. However, the quantification of DMEs in subcellular fractions 
usually suffers from batch-to-batch variability in recovery and enrichment of proteins (Xu 
et al., 2018). Therefore, we developed a simple whole tissue lysate method for 
simultaneous quantification of hepatic drug metabolism enzymes in human liver using LC-
MS/MS. The method was applied to study the effect of NAFLD on the expression of 
clinically important drug disposition proteins (phase-I and phase-II proteins). The effect of 







Materials and Methods 
Chemicals and Reagents 
 Protein preparation kit, TPCK-treated trypsin, trypsin digested β-galactosidase, and 
mass spectrometer tuning solution was from AB Sciex, Framingham, MA.  Aquity UPLC 
Peptide BEH C18 analytical column and VanGuard pre-columns were procured from 
Waters Corp. (Waltham, MA). Calbiochem ProteoExtract Native Membrane Protein 
Extraction Kit was purchased from EMD Millipore (Billerica, MA). 1,4-Dithiothreitol 
(DTT) was obtained from Roche Diagnostics (Indianapolis, IN). Sodium deoxycholate and 
iodoacetamide (IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade 
acetonitrile and formic acid were purchased from ThermoFisher, Waltham, MA. Aquity 
UPLC Peptide BEH C18 analytical column and VanGuard pre-columns were procured 
from Waters Corp., Waltham, MA.  
Human liver and homogenate preparation 
Frozen human liver samples from brain dead donors were purchased from Sekisui 
XenoTech LLC, Kansas City, KS. The detailed demographics of the donors are given in 
table 1. Livers were graded by a histopathologist as previously described and were 
categorized as control, NAFL (steatosis) or NASH (Jamwal et al., 2018). Samples were 
randomly ordered, and the liver homogenate was prepared in homogenization buffer (8 M 
urea, 50 mM Triethylammonium bicarbonate, 10 mM DTT’, v/v). Briefly, liver tissue (~50 
mg) was weighed and homogenized in 1000 µl of HB. Tissue was homogenized on an 
Omni bead homogenizer as described previously (Jamwal et al., 2017). Further, samples 




concentration of the resulting sample was determined using Pierce BCA protein assay kit 
(ThermoFisher Scientific, Waltham, MA). Lipid peroxidation and total cholesterol were 
measured as described previously (Jamwal et al., 2017).  
Pressure-cycling technology (PCT) aided trypsin digestion  
Protein digestion was conducted as described previously, with few adaptations 
(Prasad et al., 2014; Jamwal et al., 2017). Protein samples (250 µg protein) were spiked 
with 2 µg BSA and denatured with 25 µL DTT (100 mM) at 35°C for 30 min in a shaking 
water bath (100 rpm). After denaturation, samples were alkylated in the dark with 25 µL 
IAA (200 mM) for 30 min at room temperature. Samples were subsequently concentrated 
using the cold water, methanol and chloroform (1:2:1) precipitation method (centrifugation 
at 10000 rpm, 5min at 10°C). The protein pellet was washed with ice-cold methanol and 
then suspended in 100 µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v 
sodium deoxycholate (DOC). Further, TPCK-treated trypsin (10 µg) was added to samples 
at a ratio of 1:25 (trypsin: protein) and samples were transferred into digestion tubes (PCT 
MicroTubes, Pressure Biosciences Inc., Easton, MA). The barocycler was run at 35°C, for 
75 cycles with 60 sec per pressure-cycle (50-sec high pressure, 10-sec ambient pressure, 
25 kpsi). Subsequently, 10 µg trypsin was again added to each sample and barocycler based 
digestion was repeated at the specifications mentioned above. 
Further, to 110 µL of digested peptides sample, 10 µL of ACN/water (1:1, v/v containing 
5% formic acid) was added to precipitate detergent (snow white pellet). Samples were spun 
to remove the pellet and 100 µL supernatant was collected (10,000 rpm for 5 min at 10°C). 




(∼15 pmol). Samples were spun (10,000 rpm for 5 min at 10°C) again to remove pellet if 
any. Subsequently, twenty-five microliters of the resulting peptide solution was injected 
on the analytical column and samples were analyzed using LC-MS/MS method described 
below.  
LC-MS/MS Analysis 
 Data-dependent analysis (DDA) was performed in positive ionization mode using 
a DuoSpray™ ion source on a Sciex 5600 TripleTOF™ mass spectrometer (AB Sciex, 
Concord, Canada) equipped with an Acquity UPLC HClass system (Waters Corp., 
Milford, MA, USA).  Gas 1 (GS1), gas 2 (GS2) and curtain gas (CUR) were maintained 
at 55, 60 and 25 psi, respectively.  Ion spray voltage floating (ISVF) was kept at 5500 V 
while the source temperature (TEM) was 500°C. Declustering potential (DP), collision 
energy (CE) and collision energy spread (CES) were set at 120, 10 and 5 respectively. 
During the survey scan, all the ions with a charge state of 2 to 4, mass range of m/z 300-
1250 and exceeding 25 cps were used for MS/MS analysis. Former target ions were 
excluded for 8 sec and the mass tolerance for TOF-MS was 50 mDa with a 100 milliseconds 
accumulation time. For product scan, data was acquired from 100 to 1250 m/z with an 
accumulation time of 75 millisecond with a total cycle time of 3.5 sec. Product ion analysis 
was done under dynamic accumulation and rolling collision energy dependent on the m/z 
of the ion. 
Chromatographic separation was achieved over 180 min gradient method at 100 
μL/min on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) preceded 
by an Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). Mobile phase A 




acetonitrile, 2% water, 0.1% formic acid).  Gradient conditions used were 98% A from 
0 to 5 min, 98% to 70% A from 5 to 155 min, 70% to 50% A from 155 to 160 min, 50% 
to 5% A from 160 to 170 min, 5% to 98% A held from 170 to 175 min. The gradient 
was held at initial conditions from 175 min until the end of the run to equilibrate the 
column before the start of next run.  The flow was diverted to waste for the first 8 minutes 
and last 20 minutes of the acquisition. Autosampler was maintained at 10°C, and the 
column was kept at 50°C. Trypsin-digested β-galactosidase peptides were injected to 
monitor TOF detector mass calibration every four sample. 
Data processing  
The absolute level of proteins was determined from DDA data using “Total Protein 
Approach”(Wisniewski and Rakus, 2014). Homogenate samples were analyzed as 
previously described using MaxQuant (ver 1.5.2.10) (Wisniewski and Rakus, 2014; 
Jamwal et al., 2017). The proteins were searched on Andromeda search engine against the 
Swiss-Prot human protein database (updated Apr 2018) at 1% false discovery rate 
(FDR)(Cox and Mann, 2008). Cysteine carbamidomethylation was selected as fixed 
modifications for the search. Oxidation (M) and acetyl (protein N-term) were used as a 
variable modification in protein quantification. Label-free quantification (LFQ) was 
performed with a ratio count of 1, and a maximum of two missed cleavages was allowed. 
Unique peptides were selected for protein quantification while all the other MaxQuant 
settings were kept as default values. The absolute protein levels were calculated using 
“Total Protein Approach” from raw intensities obtained from MaxQuant (Wisniewski and 
Rakus, 2014). The protein concentrations were expressed as picomoles of protein per gram 









Protein conc. (p) =
MS signal (p) × 106
Total MS signal ×  MW(p) 
 [pmol/mg homogenate protein] 
 
Normalized Protein conc. (p) = Protein conc (p) × PPGL ×  NF  [pmol/g liver] 
 
 
where MS signal (p) refers to total LFQ signal intensity for a protein of interest. Total MS 
signal indicates to the total LFQ intensity of all the proteins in the sample and MW 
represents the molecular weight of respective protein. PPGL denotes the yield of 
milligrams of total protein per gram of liver tissue.  
 
Statistical analysis 
Q-Q plot was used to determine the normality of the protein samples. After 
determining that the protein samples violated the assumption of normal distribution, non-
parametric tests were used for all the analyses. Non-parametric Mann-Whitney U test was 
used to compare the differences for two groups and Kruskal-Wallis for comparison of three 
or more groups. The vendor provided functional activity was used for correlation analysis 
with protein concentration. The details of the assay’s conditions are described elsewhere 
(Jamwal et al., 2017). Spearman-correlation analysis was performed between the 




moderate (r=0.5-0.7) or weak (r=0.3-0.5). P < 0.05 was considered significant throughout 
the analysis. Data are reported as geometric mean and 95% confidence interval unless 
stated otherwise. Prism 6 (GraphPad Inc., La Jolla, CA) and SPSS 23 (IBM Corp., Armonk, 




















NAFL and NASH liver samples exhibited significantly elevated levels of malondialdehyde 
and cholesterol (Table 1). The livers from NAFL and NASH donors were larger in weight 
than the control group.  The total protein yield from samples with NAFLD was marginally 
lower as compared to the control. Donors with NAFLD also showed a trend of increased 
body weight and body mass index. The geometric mean of ????? for the control group was 
marginally lower than the NAFLD groups. The yield of protein per gram liver (mg/g) was 
slightly lower from NAFL and NASH groups as compared to control.   
Effect of NAFLD on the expression and activity 
 The protein expression of CYP1A2 was significantly lower in NAFLD samples 
(p<0.05). There was a discernible decrease in CYP3A4 and CYP3A5 levels in NAFL and 
NASH livers but the effect was not significant due to high interindividual variability (figure 
1). We observed no change in the protein levels of CYP2E1, CYP2D6, CYP2C8, and 
CYP2C9 among different study groups (table 2). A trend of lower expression was observed 
for CYP2B6; however, the reduction was not significantly different from control samples. 
Cytochrome b5 was downregulated considerably as the severity of disease increased. There 
was no change observed for the amount of CPR between the different groups. The protein 
levels of CYP8B1, CYP27A1, and CYP51A1 were also similar among three study groups. 
 Similar to protein abundance, CYP1A2 phenacetin O-dealkylation activity was 
significantly lower in NAFL and NASH (figure 2). CYP3A4 mediated testosterone 
hydroxylation was moderately decreased in NAFLD group. The activity of other CYP450 




Furthermore, we did not see any significant differences in the protein expression of any of 
the UGTs included in the study (table 3, figure 3). Interestingly, SULT1A1 and SULT2A1 
expression were lower in NAFL, but levels were similar for NASH and control livers (table 
3).  No significant alteration in SULT1C1 and SULT1A2 levels was observed (figure 4). 
A comprehensive list of other hepatic proteins studied, and the effect of NAFLD is given 
in supplementary table 1.  
Correlation of CYP450 enzyme activity and protein expression 
Non-parametric Spearman correlation analysis was performed between the 
determined protein levels and vendor provided enzyme activity (figure 5). A significant 
correlation with varying strength was observed for all the 9 CYP450 enzymes. CYP1A2, 
2A6, 2B6, 3A4 exhibited strong correlation (r>0.7) while it was moderate (r=0.5-0.7) for 
CYP2C8, 2D6 and 3A5. Interestingly, the association between CYP2C9 protein and 
activity was weakest (r=0.48) among all the proteins.  
Biomarker proteins in NAFLD 
Carbamoyl-phosphate synthase (CPS1), acyl-CoA dehydrogenase short/branched 
chain (ACADSB) and acyl-CoA synthetase medium-chain family member 5 (ACSM5) 
were significantly downregulated in NAFLD (table 3). In contrast, acyl-CoA synthetase 
medium-chain family member 3 (ACSM3) levels were significantly lower in NAFL but 
not NASH. The protein expression of fatty acid synthase (FASN) was unchanged in NAFL 
but was elevated in NASH (Fig 6). Hepatic glyoxalase 1 (GLO1) levels were moderately 






Variable effects were observed on the expression of most proteins suggesting involvement 
of complex transcriptional, translational, epigenetic and/or polymorphic regulatory events. 
Oxidative stress and lipid peroxidation play a significant role in the pathogenesis of 
NAFLD (Masarone et al., 2018). Studies in human have found elevated levels of 
malondialdehyde (MDA) and other markers of oxidative stress in NAFLD (Kumar et al., 
2013). Higher cholesterol is also a significant risk factor for development and progression 
of the disease (Ioannou, 2016). The protein expression of CYP8B1 and CYP27A1 (bile 
acid synthesis) and CYP51A1 (cholesterol synthesis) was similar among three groups 
suggesting other mechanisms (uptake or efflux) for cholesterol accumulation may be at 
play in NAFLD. Suppressed cholesterol efflux capacity has been reported in NAFLD 
patients (Fadaei et al., 2018). No downregulation of CYP51A1 and CYP8B1 in NASH 
biopsy samples was reported in the Japanese population (Kakehashi et al., 2017). CYP4F2 
level initially increased during acute lipid insult (hepatoprotective mechanism) but was 
found to be downregulated during chronic stimulation (hepatotoxicity) (Bartolini et al., 
2017).  
Studies in human liver microsomes have shown downregulation of CYP3A activity 
with the progression of disease and severity of steatosis (Kolwankar et al., 2007; Fisher et 
al., 2009). The plasma midazolam concentration in NASH patients was 2.4-fold higher 
than the control subjects (Woolsey et al., 2015). A recent study from our group found 
almost a 2-fold decrease of CYP3A4 protein expression and activity in liver microsomes 




livers found significant downregulation of CYP3A4 protein and activity but not mRNA 
(Dostalek et al., 2011).  
Downregulation of CYP1A2 protein and activity has been reported in human liver 
microsomes and hepatocytes from fatty liver grafts (Donato et al., 2006; Fisher et al., 
2009). Dysregulated cytokine and the chemokine-mediated inflammatory response is 
typical in NAFLD and plays a pivotal role in its pathophysiology (Braunersreuther et al., 
2012). Elevated proinflammatory cytokines in NAFLD have been reported, and this may 
partially explain the downregulation of CYP1A2 and CYP3A4 activity and protein 
observed in our study (Liptrott et al., 2009). In contrast to other reports of significant up-
regulation of CYP2A6 in NAFLD, we found a marginal decrease in the protein expression 
of the enzyme (Wang et al., 2018). The coumarin hydroxylation activity of the enzyme was 
similar between control and NAFLD livers. Donato et al. found significant downregulation 
of CYP2A6 mRNA and activity in a hepatocyte model of cellular steatosis (Donato et al., 
2006).  
CYP2E1 mediated biotransformation reactions in liver generate a significant 
amount of reactive oxygen species which further promote the oxidative stress in NAFLD 
(Aubert et al., 2011). In contrast to reports of elevated CYP2E1 in NAFL and NASH, we 
found that the protein expression and functional activity was similar among the three 
groups (Leung and Nieto, 2013). CYP2E1 mRNA and protein expression were found to be 
lower in another study in livers from NAFLD patients whereas activity was unaltered 
(Fisher et al., 2009). Fatty acid treatment in cultured HepG2 cells did not induce CYP2E1 




ratio) in patients with NAFLD was unable to distinguish NASH from NAFL (Chtioui et 
al., 2007).   
CYP2C8 protein expression was downregulated in NASH-associated liver biopsy 
while CYP2C9 levels were unchanged compared to control (Kakehashi et al., 2017). Other 
studies in human tissue also observed no changes in the expression of either isoforms 
(Chtioui et al., 2007). CYP2C8 activity was similar in different stages of NAFLD and 
control livers whereas CYP2C9 activity was reported to be higher (Fisher et al., 2009). A 
recent study in 3-dimensional hepatocyte culture model of NAFLD, CYP3A4 activity was 
found to be upregulated while CYP2C9 decreased (Kostrzewski et al., 2017). We could 
not determine the levels of CYP2C19 in our study and is one of the limitations of the 
homogenate-based method in which low abundance proteins are not measured due to a 
limited dynamic range of quantification.  
CYP2B6 is one of most polymorphic enzymes which accounts for significant 
variability in its expression and activity (Zanger and Klein, 2013). Fisher et al. observed 
elevated CYP2B6 mRNA without any change in protein and activity during the progression 
of NAFLD (Fisher et al., 2009). Similar to CYP2B6, CYP2D6 is another highly 
polymorphic enzyme responsible with varying phenotypes and degree of metabolism of its 
substrates (Zhou, 2009).  Current literature reports no significant alterations in CYP2D6 
expression and activity in human liver (Fisher et al., 2009). A revisit to protein and activity 
data with information of polymorphism may help to ascertain the changes associated with 




UDP glucuronosyltransferases (UGTs) are involved in phase-II metabolism 
(glucuronidation) of 40–70% of all clinical drugs in human and also detoxify endogenous 
compounds (Jancova et al., 2010; Rowland et al., 2013). While the effect of NAFL on 
CYP450 enzymes has been extensively studied, only limited information on the regulation 
of UGTs is available in human (Hardwick et al., 2013). Hardwick and colleagues identified 
significant alterations in mRNA of different UGT isoforms, but the acetaminophen 
glucuronidation activity was unchanged (Hardwick et al., 2013). UGT2B17 and UGT2B7 
were identified to have similar protein levels between control and NASH biopsy samples 
(Kakehashi et al., 2017) . Yalcin et al. also found that SULT1A1 protein expression and 
activity were significantly decreased in steatosis (Yalcin et al., 2013). Other have reported 
downregulation of human SULT1A2 in NAFLD (Younossi et al., 2005; Stepanova et al., 
2010). In contrast, the elevated SULT1A1 protein was observed in steatosis, but it was 
found to be downregulated in NASH (Hardwick et al., 2013).  Similar to reports for 
CYP450 enzymes, regulation of UGT and SULT is as heterogeneous; however, there is a 
scarcity of data for the later.  
 Mitochondrial distress and oxidative stress are common in NASH (Simoes et al., 
2018). Studies have reported reduced anti-oxidant defense capacity in NASH (Koliaki et 
al., 2015).   Significant suppression of numerous mitochondria associated proteins was 
observed in NAFLD samples. Differential expression of FASN has been reported in 
literature with common consensus on the increase in the levels of enzyme with the 
progression of steatosis (Dorn et al., 2010). Acyl-CoA dehydrogenase short/branched chain 
(ACADSB) is a mitochondrial enzyme involved in the metabolism of fatty acid and 




fold lower in patients with NASH versus obese controls (Younossi et al., 2005). 
Concurrently, a decrease in the mitochondrial enzymes (ACSM3, ACSM5) involved in 
fatty acid oxidation was observed.  
 GLO1 is involved in metabolism of reactive glyoxyal and methylglyoxal 
metabolites thereby preventing glycation of proteins. Decreased levels of GLO1 were 
recently identified in pediatric NAFLD biopsy samples (Spanos et al., 2018). A decrease 
in GLO1 (as observed in our study) may be responsible for elevated levels of 
methylglyoxal-derived advanced glycation end product observed in serum of NAFLD 
patients (Spanos et al., 2018). Downregulation of CPS1 and dysregulation of the urea cycle 
in NAFLD has been described in literature (De Chiara et al., 2018). Accumulation of urea 
leads to scar tissue development, one of the complications of NAFLD. The gradual 
decrease from control to NAFL and NASH samples in CPS1 expression was reported 
previously (Rodriguez-Suarez et al., 2010).  
The sampling of human liver tissue is critical in the identification of the 
perturbations in the expression of DDPs. We speculate that the differences in the sampling 
may have presented some of the observed results in our study. Histopathological 
differences were found in liver biopsies from the right and left lobes of bariatric patients 
(Merriman et al., 2006). Given these results are primarily limited to Caucasian population, 
care should be taken for extrapolation of the results. The availability of human liver tissue 
for studying the hepatic xenobiotic transporters remains a challenge for researchers due to 
ethical consideration and the availability of tissue with adequate clinical information. Our 




to the information passed on by the vendor. Furthermore, there was no data available on 
the duration of hospitalization of donors before the organs were harvested.  
NAFLD is often accompanied by other comorbidities (obesity, diabetes) which 
may confound the observations and could partially explain the wide discrepancy in the 
literature. While we accounted for the NAFLD with and without diabetes, small sample 
size deterred us from conducting statistical analysis of any sort (supplementary table 2-6). 
Therefore, the results and discussion of this work are mainly restricted to the effect of 
NAFLD on the expression of DMEs without any focus on underlying comorbidities.  
To summarize, our research suggests that most drug metabolizing enzymes apart 
from CYP1A2 and CYP3A appears to be largely unaffected by NAFL and NASH. A lack 
of adverse clinical reports also indicates that most drugs appear to be well-tolerated by 
these patients despite the changes in the expression of drug metabolism enzymes. An 
understanding of metabolism, as well as transport protein, may provide a better picture of 
the clinical manifestations of the perturbed proteins in NAFLD. Multiple factors in NAFLD 
may affect the expression and activity of DDPs, and comprehensive study needs to be 
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Figure 1: Effect of NAFLD on protein expression of various CYP450 proteins. Graphs 
represent Tukey box plots with median (horizontal line); + represent mean; P-value from 
non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent 





Figure 2: Effect of NAFLD on functional activity of various CYP450 proteins. Graphs 
represent Tukey box plots with median (horizontal line); + represent mean; P-value from 
non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent 











Figure 3: Correlation of protein expression and functional activity of CYP enzymes. 






Figure 4: Effect of NAFLD on protein expression of UGT proteins. Graphs represent 
Tukey box plots with median (horizontal line); + represent mean; P-value from non-
parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent p-






Figure 5: Effect of NAFLD on protein expression of SULT proteins. Graphs represent 
Tukey box plots with median (horizontal line); + represent mean; P-value from non-
parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent p-








Figure 6: Effect of NAFLD on protein expression of some marker proteins in NAFLD. 
Graphs represent Tukey box plots with median (horizontal line); + represent mean; P-value 
from non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** 



































Table 1: Demographic characteristics of control, NAFL and NASH groups. BMI: 
Body-mass index; PPGL: Protein per gram liver. P-value from non-parametric Kruskal-

















































































































































































































































































































































































































































































































Table 2: Effect of NAFLD on the expression of major CYP450 enzymes and 
auxiliary proteins. P-value from non-parametric Kruskal-Wallis test and Dunn’s 
































Table 3: Effect of NAFLD on the expression of major UGT enzymes. P-value from 
non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent 


























































































































































































































































































































































































































































































































































































































































































































































































Table 4: Effect of NAFLD on the expression of NAFLD specific marker proteins. P-
value from non-parametric Kruskal-Wallis test without adjustment for multiple 

















































































































































































































































































































































































Supplementary Table 1: Effect of NAFLD on protein expression of other drug disposition 
proteins. 
Supplementary Table 2: Donor demographics for NAFL and diabetes 
Supplementary Table 3: Effect of NAFLD and diabetes on the expression of CYP450 
proteins. 
Supplementary Table 4: Effect of NAFLD and diabetes on protein expression of phase-II 
proteins.  
Supplementary Table 5: Effect of NAFLD and diabetes on protein expression of some 
marker proteins. 
Supplementary Table 6 a,b: Effect of NAFLD and diabetes on protein expression of 
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Hepatic xenobiotic transporters in human liver play an important role in the elimination of 
drugs or toxins and significantly contribute to variability in drug response. We developed 
a label-free mass spectrometry-based method to study the protein expression of 25 
clinically relevant transporter proteins (12 ABC and 13 SLC) in liver tissue from 22 donors 
(9 female, 12 male).  Membrane fractions were extracted from the tissue using 
ProteoExtract membrane extraction kit and in-solution trypsin digestion was performed 
using pressure-cycling technology. Data was acquired in data-dependent and sequential 
window acquisition of all theoretical mass spectra (SWATH-MS) mode. Chromatographic 
separation was achieved over a 90-min gradient on Acquity UPLC BEH C18 peptide 
column, and mass spectrometer was operated in positive electrospray mode. Digested E. 
coli β-galactosidase peptides were spiked in each sample before LC-MS/MS analysis, and 
intensity was expressed relative to APLDNDIGVSEATR peptide.  ProteinPilot (ver 5.0.1) 
was used for peptide identification and Skyline (ver 4.0) was used for targeted data 
extraction from SWATH files. Na+/K+ transporting subunit alpha 4 (ATP1A4), was 
quantified as a cell membrane marker and its coefficient of variation was 9.7% across 
different liver samples. 
Significance: The work highlights the suitability of SWATH-MS for large-scale 
simultaneous quantification of several xenobiotic transporters important in drug 
disposition. We found that average differential expression of transporters proteins was 






Xenobiotic transporters play a crucial role in drug disposition by mediating drug uptake 
and efflux.  These proteins govern the absorption, distribution, metabolism, and elimination 
of drugs, toxins and endogenous molecules across the cell membrane. Thus, transporters 
can govern the rate-limiting step in systemic and tissue exposure of drugs. Biologically, 
transporters are membrane-bound proteins which are ubiquitously expressed throughout 
the body. These proteins are mostly localized on the apical or basolateral membranes of 
various organs including intestine, liver, kidney, and brain and facilitate the efflux and 
uptake of xenobiotics [1]. The ATP-binding cassette (ABC) family and the solute carrier 
(SLC) family represent the two significant super families of membrane transporters in 
human [2-4]. ABC transporters utilize ATP for transport of substrates across the 
membrane, and most of efflux transporters belong to this family (Supplementary table 1a).  
In contrast, SLC transporters mainly facilitate uptake which can be active or facilitated 
(Supplementary table 1b). Some SLC transporters also mediate bidirectional movement of 
molecules. The altered systemic exposure and organ toxicity can be related to transporters 
mediated drug interactions [1, 5]. Therefore, the last decade has seen a significant amount 
of research focusing on quantification and de-orphanization of these transporters as well as 
elucidation of their functionality [6, 7].  Inter-individual variability in the expression and 
drug response of xenobiotic transporters may arise from non-genetic (age and gender), 
genetic (polymorphism), epigenetic and regulatory factors [8].  While more than 400 
different transporters have been annotated in the human genome, the function of many of 




Efflux transporters localized on the canalicular membrane (e.g., P-gp/MDR1, MRP2, 
BCRP, BSEP, MDR3, and MATE1) facilitate excretion of molecules from hepatocytes 
into bile [4, 6, 10]. Meanwhile, basolateral hepatic efflux transporters (e.g., MRP1, MRP3, 
MRP4, MRP5, and MRP6) return molecules to hepatic blood from the hepatocyte [4, 6, 
11].  Prominent uptake transporters that are localized on the sinusoidal membrane of 
hepatocyte include NTCP, OATP1B1, OATP1B3, OATP2B1, OAT2, and OCT1 [12, 13].  
These uptake transporters, facilitate uptake of drugs from the blood into hepatocyte thereby 
facilitating metabolic clearance of drugs.  Moreover, OAT7 on the sinusoidal membrane 
and sterolin-1 and sterolin-2 on basolateral membrane mediate bidirectional (efflux and 
uptake) transport of various substrates [14, 15]. 
Traditionally, researchers have relied on quantification of mRNA expression of 
transporters as a surrogate to the functional activity in the tissue.  However, a weak 
correlation was observed between mRNA and protein expression in human livers [16, 17]. 
Protein abundance levels of these transporters are usually estimated by cumbersome 
Western blot analyses that is semi-quantitative at best. Last decade has seen a rise in the 
use of mass-spectrometry (MS) based techniques for quantification of the protein 
expression [10, 18]. Available MS methods for quantification of liver transporters are 
based on targeted quantitative proteomics approaches [10, 16, 17, 19, 20]. A 
comprehensive cost comparison of different mass spectrometry-based techniques reported 
significant cost savings with label-free based quantitative proteomics [21].  LFQ 
approaches are relatively inexpensive as compared to targeted MRM methods as there is 
no need to synthesize unique peptides for each protein and isotopically labeled isoforms of 




Relative label-free quantification (LFQ) using the sequential window acquisition of all 
theoretical mass spectra (SWATH-MS) technique provides an alternative to targeted 
approaches for protein estimation [22]. SWATH is a data-independent acquisition (DIA) 
technique in which all the precursors within a predefined m/z are fragmented, and product 
ions of these precursors are recorded as a digital repository [23]. The data is further 
deconvoluted and extracted using software like OpenSWATH, SWATH 2.0 and Skyline 
[24]. A significant advantage of SWATH-MS over the other mass spectrometry methods 
is related to the ability to perform retrospective mining of the data. For instance, if the 
researcher comes up with a new hypothesis in the future, SWATH-MS data would allow 
interrogation of the existing data for additional protein/s of interest without the need for 
sample digestion or data reacquisition. Such a strategy offers a tremendous benefit 
concerning saving of sample, time and money. A high linear association between MRM 
based methods with SWATH-MS has been shown in the past making it a suitable and 
reliable technique for proteomics-based studies [25, 26]. Nakamura et al. also described a 
SWATH-MS for quantification of drug-related transporter proteins in human liver 
microsomes, however no gender specific differences were reported due to use of small 
sample size (n=4) [25].  
In this work, we report the development of a SWATH-MS based method to study the 
gender-specific differential expression of important drug and xenobiotic transporters in 
human liver (12 ABC and 13 SLC family). The transporter proteins were shortlisted based 
on the recommendation made by the International Transporter Consortium (ITC), the US 
Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), as 




2. Materials and methods 
2.1 Chemicals and Reagents 
Protein preparation kit, TPCK-treated trypsin, trypsin digested β-galactosidase, and MS 
tuning solution was obtained from SCIEX (Framingham, MA).  Acquity UPLC Peptide 
BEH C18 analytical column and VanGuard pre-columns were procured from Waters Corp. 
(Waltham, MA). Calbiochem ProteoExtract Native Membrane Protein Extraction Kit was 
purchased from EMD Millipore (Billerica, MA). 1,4-Dithiothreitol (DTT) was obtained 
from Roche Diagnostics (Indianapolis, IN). Sodium deoxycholate and iodoacetamide 
(IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade acetonitrile and 
formic acid were purchased from ThermoFisher (Waltham, MA). 
2.2 Human Liver Bank 
Frozen human liver samples from brain dead donors were purchased from Sekisui 
XenoTech LLC, Kansas City, KS. All the livers are from organ donors involved in 
automobile accidents and therefore are IRB-exempt.  The age of liver donors ranged from 
21 to 64 years, with 13 males and 9 females.  Most livers were from organ donors involved 
in automobile accidents.  The detailed demographics of the donors is given in table 1.   
2.3 Human Liver Tissue Preparation 
Membrane extraction from human tissue was performed as described in the ProteoExtract 
kit protocol with slight modifications.  Briefly, liver tissue (~100 mg) was placed in a 
Dounce homogenizer with 1000 µl of extraction buffer-I (EBI) and five µl of the protease 




otherwise. Tissue was homogenized on ice with 10-15 strokes and incubated for 10 min 
with gentle agitation. Samples were spun at 16,000 x g for 15 min, and the supernatant was 
stored for future analysis of soluble proteins.  The remaining pellet was gently resuspended 
in 500 µl of extraction buffer-II (EBII) and 2.5 µl of the protease inhibitor cocktail.  
Following 30 min incubation with gentle agitation, samples were centrifuged at 16,000 x 
g for 15 min, and the supernatant containing the membrane-bound and associated proteins 
was collected for further analysis. Total protein concentration was estimated using Pierce 
BCA protein assay kit (ThermoFisher Scientific, Waltham, MA). 
2.4 Pressure-Cycling Technology (PCT) aided trypsin digestion 
Protein digestion was performed as described by Prasad et al. with modifications [28]. 
Membrane fractions (250 µg protein) were denatured with 25 µL DTT (20 mM) at 95°C 
for 15 min in a shaking water bath (100 rpm). After denaturation, samples were alkylated 
in the dark with 25 µL IAA (33 mM) for 30 min at room temperature. Samples were 
subsequently concentrated using the cold methanol, chloroform, and water (2:1:1) 
precipitation method. Samples were washed with ice-cold methanol and then resuspended 
in 75 µL of 50 mM ammonium bicarbonate (pH 7.8) containing 3% w/v sodium 
deoxycholate (DOC). Further, TPCK-treated trypsin was added to samples at a ratio of 
1:20 (trypsin: protein) and samples were transferred into digestion tubes (PCT MicroTubes, 
Pressure Biosciences Inc., Easton, MA). The barocycler was run as described previously 
by our group [29]. Post tryptic digestion, 20 µL of 2.5% formic acid in 50:50 water: 
acetonitrile was added to 80 µL of digested protein samples to precipitate DOC and any 
undigested proteins as well as quench the trypsin digestion. Samples were spun at 5000 g 




spiked with trypsin-digested β-galactosidase peptides (15 pmol) before mass 
spectrometry analysis and 15 µL was injected.  
2.5 LC-MS/MS Analysis 
Mass spectrometry analysis was performed as described previously with modifications 
[29].  All experiments were performed on a SCIEX 5600 TripleTOF® mass spectrometer 
equipped with a DuoSpray™ ion source (SCIEX, Concord, Canada) coupled to Acquity 
UHPLC HClass system (Waters Corp., Milford, MA, USA). Sample separation was 
achieved on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm2, 300 Å, 1.7 µm) 
attached to an Acquity VanGuard pre-column (2.1 X 5 mm2, 300 Å, 1.7 µm). 
Autosampler and analytical column were maintained at 10°C and 40°C, respectively. 
The chromatographic separation was achieved over a 90-min gradient at 100 μL/min. A 
linear gradient was used for chromatographic separation using mobile phase A (98% 
water, 2% acetonitrile, 0.1% formic acid) and mobile phase B (98% acetonitrile, 2% 
water, 0.1% formic acid).  The solvent composition was 98% A from 0 to 5 min, 98% 
to 75% A from 5 to 55 min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to 
70 min, 20% A held from 70 to 75 min to flush the column back to 98% A at 80 min. 
The gradient was held at initial conditions from 80 min until the end of the run to 
equilibrate the column before the start of next run. Mass calibration of the QTOF 
detector was monitored by injecting trypsin-digested β- galactosidase peptides every ten 






2.6 Data-dependent and SWATH acquisition parameters 
Data-dependent, as well as data independent (SWATH) analysis, was performed in positive 
ionization mode. The method specific parameters were as follows: gas 1 (GS1) 60 psi, gas 
2 (GS2) 60 psi, curtain gas (CUR) 25 psi.  The source-specific parameters were: 
temperature (TEM) 450°C, ion spray voltage floating (ISVF) 5500 V, declustering 
potential (DP): 120, collision energy (CE) 10, collision energy spread (CES) 5.  
A maximum of 50 candidate ions with a charge state 2 to 4 was monitored every survey 
scan cycle. All the ions between m/z 300-1250 which exceeded 25 cps were subjected to 
MS/MS analysis.  Rolling collision energy dependent on the m/z of the ion and dynamic 
accumulation were used. The mass tolerance was set at 50 mDa during the initial 0.25 sec 
survey scan (total cycle time: 3.90 sec).  
All the parameters for SWATH acquisition were similar as described above except the 
following: Source temperature (TEM) was 400°C, GS 1 was 55 psi, and TOF masses were 
collected from m/z 300 to 1500. The total cycle time for SWATH acquisition was 3.95 sec. 
SWATH data was acquired (m/z 400-1100) over 70 SWATH windows per cycles with a 
window size of m/z 10.  
2.7 Data processing and extraction 
DDA samples were searched against reviewed Swiss-Prot identifiers (October 2016) using 
ProteinPilot 5 (SCIEX, Concord, Canada).  The search was performed using Paragon 
algorithm for identification of peptides and proteins from DDA data. Thorough ID search 
mode with digestion: trypsin, Cys alkylation: iodoacetamide with false discovery analysis 




processing was maintained on biological modifications only. Raw data files and search 
results are available at Japan Proteome Standard Repository (jPOSTrepo JPST000372, 
ProteomeXchange PXD008593), a publicly available data repository for proteomics data 
[30]. Spectral library and SWATH data were uploaded to Skyline for peptide and transition 
picking. Skyline is an opensource application for targeted extraction of peptide information 
from the SWATH data. Surrogate flyable peptides were selected as previously described 
[31]. For each protein, peptide correlation analysis was performed to choose surrogate 
peptides with a significant correlation coefficient (Spearman r>0.500, P<0.05). Only 
peptides between 6 to 25 amino acids, that were not embedded in the transmembrane 
domain were included. We also excluded peptides with known posttranslational 
modifications and polymorphic variations.  Wherever possible, two peptides per protein 
were used to estimate the relative abundance of transporter proteins.   
2.8 Data normalization 
The raw peptide intensity data was expressed relative to the β-galactosidase peptide 
(APLDNDIGVSEATR [M + 2H]2+: 729.3652) intensity. Subsequently, these relative 
values were normalized with membrane protein yield to account for the differences in 
protein abundance among samples. 
Relative intensity =
Raw intensity (protein)
Raw intensity (APLDNDIGVSEATR) 
 
Normalized intensity = Relative intensity ∗ membrane protein per mg tissue 





2.9 Statistical analysis 
The correlation analysis for selection of surrogate peptides and statistical analysis was 
performed on Prism 6 (GraphPad Software Inc. La Jolla, Ca). Non-parametric Mann 
Whitney U test was used to compare the differences in demographic data and Chi-square 
test was used to compare the proportionality. Normalized intensity data were natural-
logarithm transformed before statistical analysis [32]. The geometric mean was calculated 
from non-transformed data using SPSS v24 (IBM Analytics, Armonk, NY). Gender 
differences in the relative expression of major xenobiotic and drug transporters in human 
liver were carried out using a t-test on the natural logarithmic transformed data. Non-
parametric Spearman analysis was used for correlation between different transporter 
proteins. P<0.05 was considered significant throughout the analysis. Demographic data 












3.  Results  
SWATH-MS was used to estimate the protein expression of 25 hepatic drug transporters 
(12 ABC and 13 SLC family) in membrane fractions from 22 human liver donors. A 
complete list of surrogate peptides used for the relative estimation of transporters in liver 
samples is given in supplementary table 2. All transporters were quantified with two 
unique surrogate peptides except OATP1B1, OCT3, ENT1, NTCP, and sterolin-2 where 
only one unique surrogate peptide was qualified for inclusion based on the criteria 
described in 2.7. 
3.1 Yield of membrane protein per gram of liver tissue 
The average membrane yield (mg/g liver tissue) for all the livers was 20.33±4.42, n=22 
(fig 1a). Membrane protein yield was marginally lower in females (19.05±1.44, n=9) as 
compared to males (21.21±1.23, n=13). However, the gender-difference in yield was 
statistically insignificant (p>0.46). The variability in sodium/potassium-transporting 
ATPase subunit alpha-4 (ATP1A4, an integral membrane marker) levels was used to gauge 
the quality of the membrane fractions and % coefficient of variation among the 22 samples 
was 9.7% (fig 1b). 
3.2 Effect of gender on drug efflux transporters 
We found that none of the investigated efflux transporters was differentially expressed in 
males and females (fig 2a). BCRP was detected in membrane fractions from 7/9 female 
and 7/12 male donor livers. In females, BSEP was found in eight out of nine donors.  Other 




transporters quantified using this assay are given in fig 2b. No significant gender difference 
was seen in transporter proteins with efflux/uptake function as well (fig 2c). Sterolin-1 was 
detected in 8 and 9 membrane fractions from female and male donors, respectively. ENT2 
was detectable in membrane fraction from 8 females and 9 male donors.  
3.3 Effect of gender on drug uptake transporters 
Gender was not found to influence the protein abundance of any of the uptake transporters 
in this study (fig 3). All the uptake transporters included in the study except OATP 
transporters were detectable in all the liver samples. In males, OATP1B3, and OATP2B1 
were present in 12, and ten donor liver samples, respectively. In females, OATP1B3, and 
OATP2B1 were present in 7, and 8 donor liver samples, respectively. OAT1B1 was found 
in all the samples included in the study. Gender-specific expression level and male/female 












Drug response, efficacy, and toxicity are dependent on the expression of drug metabolizing 
enzymes and transporters in the intestine and liver.  Differences in the basal expression of 
these proteins in the human liver can contribute to significant changes in systemic exposure 
of a drug. Extensive research in human has shown the gender-related differences which 
partly explain the interindividual variability in drug disposition, toxicity and therapeutic 
response [33, 34]. Gender is an essential underlying biological factor for the development 
of personalized medicine.  A study by the US General Accounting Office found that 80% 
of FDA-approved prescription drugs withdrawn from the market between 1997-2000 were 
due to higher adverse drug-related events in women [35].  While a considerable amount of 
data is available on the gender differences in transporter protein expression in rat and mice, 
studies are lacking in human [36, 37]. Also, limited data is available for the gender 
differences in expression of transporter proteins in human since most available information 
is based on gene expression [34]. Interestingly, growing body of research is suggesting that 
mRNA serves as a poorer surrogate than protein expression for prediction of transporter 
activity [17, 28, 38].  
The availability of human liver tissue for studying the hepatic xenobiotic transporters 
remains a challenge for researchers due to ethical consideration and the availability of 
tissue with adequate clinical information. Most of the samples available from healthy 
people come from donors who have sadly passed away in automobile accidents.  Therefore, 
when possible, a judicious and parsimonious use of such tissue is warranted to obtain 
maximum data. MRM-based methods of protein quantification rely on customization of 




to quantify more than one protein at a time, the cost and method complexity increases 
exponentially with an increase in the number of target proteins [21]. Despite the benefits 
offered by SWATH-MS, there are some limitations to the methodology. First, a few of the 
low abundance transporters were quantified using one surrogate peptide. As the window 
size in SWATH increases, the noise level increases drastically and impedes the 
quantification of low abundance proteins. Second, we assume that the total cellular 
membrane protein expression serves as a surrogate for purified plasma membrane. 
Nevertheless, the advantages of this technique outweigh its drawbacks. 
We observed that the inter-individual variability seen in this study was much higher than 
the average differences between the two genders. While a study with a large sample set is 
desired to completely address the cofactors contributing to this variability, such studies are 
often limited due to lack of availability of the liver tissue. Most of the tissue that is available 
for commercial purchase is obtained from motor vehicle accidents or other brain-dead 
donors and a detailed medical history is often lacking. Therefore, the potential of 
conflicting effects from obesity, diabetes or any other undiagnosed disease cannot be ruled 
out. Interestingly, there are currently no reports for any significant alteration of transporter 
proteins in human liver. Our findings are also limited as we do not have a large enough 
sample size to separately study the effect of obesity (BMI>30) or diabetes in our sample 
set. Therefore, future studies with a larger sample size are currently being planned to 
address the high inter-individual variability and differential effect of obesity and diabetes. 
Few transporter proteins (OST, OCT3) were close to p<0.05 but failed to reach statistical 
significance possibly due to sample size constraint. Based on means and standard 




had we included a sample size of n=42. In contrast, for proteins with a very high p-value, 
significantly large and practically challenging cohort of sample would be required.   
Permeability glycoprotein 1 (P-gp) and multidrug and toxin extrusion protein 1 (MATE-1) 
are predominantly responsible for efflux of cations from hepatocyte into the bile duct. 
Prasad et al. found no association between age and gender with an expression of P-gp in 
human livers (n=64) [28]. MATE-1 was reported to exhibit significant correlation with age 
but not gender [38]. Li et al. found that the protein expression of breast cancer resistance 
protein (BCRP) in human liver tissue was almost 10-fold lower than the bile salt export 
pump (BSEP)  [39]. Low levels of BCRP, as compared to other canalicular-localized 
transporters, could explain why we were able to detect BCRP only 12 out of 20 samples. 
The hepatic expression of BCRP in previous studies in human was independent of sex and 
age [17]. Cheng et al. also found no significant gender-specific differences in human 
hepatic BSEP expression [37].  
Multidrug resistance protein 3 (MDR3) is expressed in canalicular membrane of 
hepatocytes and plays an integral role in the transport of phospholipids into the bile [40]. 
Multidrug resistance-associated protein (MRP2) plays an important role in the efflux of 
lyophilic conjugates (glutathione, glucuronate, sulfate) [41]. MRP2 is localized on the 
apical membrane of polarized hepatocytes and expressed in kidney and intestine among 
other tissues [42].  
Equilibrative nucleoside transporter 1 and 2 (ENT1 and ENT2) are ubiquitously expressed 
in tissues like human liver, heart, kidney, intestine, erythrocytes, and brain [43]. Higher 




Organic anion transporting polypeptides (OATPs) facilitate uptake of large hydrophobic 
organic anions while smaller and hydrophilic organic anions are transported by the organic 
anion transporters (OATs) [45]. OATP1B1, OATP1B3, and OATP2B1 are most notable 
transporters for drug uptake in the liver. OATP1B1 and OATP1B2 are expressed 
predominantly in liver whereas OAT2B1 is ubiquitously expressed [46]. No gender-
specific expression of hepatic OATPs was found in previous or the current studies [16, 28, 
47].  
OAT2 is highly expressed in the sinusoidal membrane of hepatocytes with lower 
expression also seen in the kidney [45]. OAT7 is exclusively expressed in the basolateral 
membrane of human hepatocytes in the liver and participate in the transport of anionic 
substances in exchange for butyrate [14]. Members of the OCT family transport organic 
cations down their electrochemical gradients [45]. OCT1 and OCT3 are predominantly 
expressed in human liver and are localized to the basolateral membrane of hepatocyte [48]. 
Prasad et al. also reported no gender differences in expression of OATPs, OATs and OCTs 
in human liver [49]. Even though OCT3 showed a trend towards higher expression in males 
in our study (P=0.051), it failed to reach significance possibly due to sample size constraint. 
Sodium/taurocholate co-transporting polypeptide (NTCP) is expressed predominantly on 
the basolateral membrane of hepatocyte and facilitates the uptake of bile acids [50]. NTCP 
mRNA expression was found to be higher in women than men, but the differences in the 
expression were statistically insignificant [37]. Organic solute transporters, OST α/OST β 
form a heterometric transporter complex which is localized on the basolateral membrane 




molecular structure [15]. These transporters are expressed in higher abundance in human 




















We developed a SWATH-MS based method for label-free, relative quantitative proteomics 
analyses of drug and xenobiotic transporters in human liver. SWATH-MS based studies 
can be used for comparative global proteomics analysis and large-scale relative protein 
quantification, especially for studies that a limited quantity of tissue is available. We 
successfully showed that the current approach could be directly applied to estimate the 
protein expression of many target proteins at once and can be further applied to study the 
difference in expression in relation to demographic characteristics or disease state. Future 
studies with a larger sample size are in progress to address other factors (disease, alcohol 







Supplementary table 1a, b: List of hepatic ABCs and SLC transporters included in this 
study  
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acquisition; ENT: Equilibrative nucleoside transporter; LFQ: Label-free quantification; 
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Tables and figure legends: 
Tables 
Table 1. Donor demographics data. P value represent the significance from Mann-Whitney 
U test. C: Caucasian, AA: Afro-American, H: Hispanic 
Table 2. Gender-specific expression levels of hepatic efflux transporters. 1Geometric mean 
(95% Confidence Interval), 2Mann-Whitney U test 
Table 3. Gender-specific expression levels of hepatic efflux/uptake transporters. 
1Geometric mean (95% Confidence Interval), 2Mann-Whitney U test 
Table 4. Gender-specific expression levels of hepatic uptake transporters. 1Geometric 
mean (95% Confidence Interval), 2Mann-Whitney U test 
 
Figures 
Figure 1. Gender difference on membrane protein abundance and ATP1A4 (a 
membrane proteins marker). Normalized intensity expressed as natural logarithm 
transform relative to β-gal peptide intensity and further normalized to membrane protein 
yield. The line represents the arithmetic mean for the respective group and individual 
values are shown as aligned dots plot. Relative Intensity not be used for comparison 
between levels of different proteins.  
Figure 2. Effect of gender on hepatic 2(a) efflux, 2(b) efflux (MRPs), and 2 (c) 
efflux/uptake transporters. Normalized intensity expressed as natural logarithm 
transform relative to β-gal peptide intensity and further normalized to membrane protein 




values are shown as aligned dots plot. Relative Intensity not be used for comparison 
between levels of different proteins.  
Figure 3. Effect of gender on hepatic uptake transporters. Normalized intensity 
expressed as natural logarithm transform relative to β-gal peptide intensity and further 
normalized to membrane protein yield. The line represents the arithmetic mean for the 
respective group and individual values are shown as aligned dots plot. Relative Intensity 





Table 1: Donor demographics data for transporter quantification. P-value represent the 
significance from Mann-Whitney U test and * represent p<0.05; C: Caucasian, AA: Afro-







Table 2: Gender-specific expression levels of hepatic efflux transporters. 1Geometric 





Table 3. Gender-specific expression levels of hepatic efflux/uptake transporters. 

















Table 4. Gender-specific expression levels of hepatic uptake transporters. 1Geometric 

















Graphical abstract: Workflow for quantification of transporter proteins in human liver 
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Figure 1: Gender difference on membrane protein abundance and ATP1A4 (a 
membrane proteins marker). Normalized intensity expressed as natural logarithm 
transform relative to β-gal peptide intensity and further normalized to membrane protein 
yield. The line represents the arithmetic mean for the respective group and individual 





Figure 2: Effect of gender on hepatic (a) efflux, (b) efflux (MRPs), and (c) 
efflux/uptake transporters. Normalized intensity expressed as natural logarithm 
transform relative to β-gal peptide intensity and further normalized to membrane protein 
yield. The line represents the arithmetic mean for the respective group and individual 
values are shown as aligned dots plot. Relative Intensity not to be used for comparison 





Figure 3: Effect of gender on hepatic uptake transporters. Normalized intensity 
expressed as natural logarithm transform relative to β-gal peptide intensity and further 
normalized to membrane protein yield. The line represents the arithmetic mean for the 
respective group and individual values are shown as aligned dots plot. Relative Intensity 















Supplementary figure 1: Hepatic transporters quantified using SWATH-MS and their 
location and transport properties  
Supplementary table 1a: Major hepatic transporters of ABC superfamily quantified in 
this study 
Supplementary table 1b: Major hepatic transporters of ABC superfamily quantified in 
this study 
Supplementary table 2: Surrogate peptide and transitions used for relative quantification 




















































Sr. no Protein 
name 




1 MDR1/P-gp ABCB1 Canalicular membrane Efflux 
2 MDR3 ABCB4 Canalicular membrane Efflux 
3 BCRP ABCG2 Canalicular membrane Efflux 
4 BSEP ABCB11 Canalicular membrane Efflux 
5 MRP1 ABCC1 Basolateral/Sinusoidal 
membrane 
Efflux 
6 MRP2 ABCC2 Canalicular membrane Efflux 
7 MRP3 ABCC3 Basolateral/Sinusoidal 
membrane 
Efflux 
8 MRP4 ABCC3 Basolateral/Sinusoidal 
membrane 
Efflux 
9 MRP5 ABCC5 Basolateral/Sinusoidal 
membrane 
Efflux 
10 MRP6 ABCC6 Basolateral/Sinusoidal 
membrane 
Efflux 
11 Sterolin -1 ABCG5 Canalicular membrane Efflux 




Supplementary table 1b 
 
 




1 OCT1 SLC22A1 Basolateral/Sinusoidal membrane Uptake 
2 OCT3 SLC22A3 Basolateral/Sinusoidal 
membrane 
Uptake 
3 OAT2 SLC22A7 Basolateral/Sinusoidal membrane Uptake 
4 OAT7 SLC22A9 Basolateral/Sinusoidal membrane Uptake/Efflux 
5 OATP1B1 SLCO1B1 Basolateral/Sinusoidal membrane Uptake 
6 OATP1B3 SLCO1B3 Basolateral/Sinusoidal membrane Uptake 
7 OATP2B1 SLCO2B1 Basolateral/Sinusoidal membrane Uptake 
8 NTCP SLC10A1 Basolateral/Sinusoidal membrane Uptake 
9 ENT1 SLC29A1 Basolateral/Sinusoidal membrane Uptake/Efflux 
10 ENT2 SLC29A2 Basolateral/Sinusoidal membrane Uptake/Efflux 
11 MATE1 SLC47A1 Canalicular membrane Efflux 
12 OSTα SLC51A Basolateral/Sinusoidal membrane Uptake/Efflux 













Supplementary table 2 
Protein Precursor 
(m/z) 
Product (m/z) Peptide, charge and transition (precursor 
charge, fragment, fragment charge) 
AT1A4 643.0238 886.5244 MQINVQEVVLGDLVEIK,   +3y8 
AT1A4 643.0238 716.4189 MQINVQEVVLGDLVEIK,   +3y6 
AT1A4 643.0238 488.3079 MQINVQEVVLGDLVEIK,   +3y4 
AT1A4 429.2400 519.2773 AAVPDAVSK,   +2y5 
AT1A4 429.2400 404.2504 AAVPDAVSK,   +2y4 
AT1A4 429.2400 308.6687 AAVPDAVSK,   +2y6+2 
OATP1B3 487.9319 535.7977 MFLAALSFSYIAK,   +3y10+2 
OATP1B3 487.9319 500.2791 MFLAALSFSYIAK,   +3y9+2 
OATP1B3 487.9319 408.2185 MFLAALSFSYIAK,   +3y7+2 
OATP1B3 570.8060 826.4458 NVTGFFQSLK,   +2y7 
OATP1B3 570.8060 769.4243 NVTGFFQSLK,   +2y6 







NVTGFFQSFK,   +2y8 
NVTGFFQSFK,   +2y7 
OATP2B1 953.9921 1439.7754 ASPDPQDVRPSVFHNIK,   +2y12 
OATP2B1 953.9921 720.3913 ASPDPQDVRPSVFHNIK,   +2y12+2 
OATP2B1 953.9921 471.2638 ASPDPQDVRPSVFHNIK,   +2y8+2 
OATP2B1 532.9579 657.3930 SSPAVEQQLLVSGPGK,   +3y7 
OATP2B1 532.9579 544.3089 SSPAVEQQLLVSGPGK,   +3y6 
OATP2B1 532.9579 445.2405 SSPAVEQQLLVSGPGK,   +3y5 
OAT2 705.4122 1325.7787 LTYGGIALLAAGTALLLPETR,   +3y13 
OAT2 705.4122 1212.6947 LTYGGIALLAAGTALLLPETR,   +3y12 
OAT2 509.5985 1086.5426 QAQLPETIQDVER,   +3y9 
OAT2 509.5985 989.4898 QAQLPETIQDVER,   +3y8 
OAT2 509.5985 860.4472 QAQLPETIQDVER,   +3y7 
OCT1 647.3158 1049.4997 MLSLEEDVTEK,   +2y9 
OCT1 647.3158 962.4677 MLSLEEDVTEK,   +2y8 
OCT1 647.3158 849.3836 MLSLEEDVTEK,   +2y7 
OCT1 440.7424 637.3919 ENTIYLK,   +2y5 
OCT1 440.7424 536.3443 ENTIYLK,   +2y4 
OCT1 440.7424 423.2602 ENTIYLK,   +2y3 
MRP1 496.2561 962.4942 QPLEGSDLWSLNK,   +3y8 
MRP1 496.2561 760.4352 QPLEGSDLWSLNK,   +3y6 
MRP1 496.2561 647.3511 QPLEGSDLWSLNK,   +3y5 
MRP1 602.6402 517.2584 SSTVGEIVNLMSVDAQR,   +3y9+2 
MRP1 602.6402 460.2369 SSTVGEIVNLMSVDAQR,   +3y8+2 
MRP1 602.6402 338.1747 SSTVGEIVNLMSVDAQR,   +3y6+2 
MRP3 682.3605 1076.5656 SSLVSALLGEMEK,   +2y10 
MRP3 682.3605 977.4972 SSLVSALLGEMEK,   +2y9 
MRP3 682.3605 890.4652 SSLVSALLGEMEK,   +2y8 
MRP3 531.2591 875.4469 ADGALTQEEK,   +2y8 
MRP3 531.2591 634.3042 ADGALTQEEK,   +2y5 
MRP3 531.2591 374.1978 ADGALTQEEK,   +2y6+2 




MRP4 767.4470 814.4563 IIVFVTFTTYVLLGSVITASR,   +3y15+2 
MRP4 767.4470 690.3983 IIVFVTFTTYVLLGSVITASR,   +3y13+2 
MRP4 538.2851 875.4833 AEAAALTETAK,   +2y9 
MRP4 538.2851 733.4090 AEAAALTETAK,   +2y7 
MRP4 538.2851 549.2879 AEAAALTETAK,   +2y5 
MRP5 738.8831 1276.6428 SLFLMEEVHMIK,   +2y10 
MRP5 738.8831 1129.5744 SLFLMEEVHMIK,   +2y9 
MRP5 738.8831 1016.4903 SLFLMEEVHMIK,   +2y8 
MRP5 443.7301 701.3729 GQEFLHR,   +2y5 
MRP5 443.7301 572.3303 GQEFLHR,   +2y4 
MRP6 452.2665 729.4618 SSLASGLLR,   +2y7 
MRP6 452.2665 616.3777 SSLASGLLR,   +2y6 
MRP6 452.2665 545.3406 SSLASGLLR,   +2y5 
MRP6 694.4008 1203.6732 ALVASLPGQLQYK,   +2y11 
MRP6 694.4008 1104.6048 ALVASLPGQLQYK,   +2y10 
MRP6 694.4008 1033.5677 ALVASLPGQLQYK,   +2y9 
BSEP 515.3062 841.5254 STALQLIQR,   +2y7 
BSEP 515.3062 657.4042 STALQLIQR,   +2y5 
BSEP 515.3062 529.3457 STALQLIQR,   +2y4 
BSEP 515.2956 829.4679 SLNIQWLR,   +2y6 
BSEP 515.2956 715.4250 SLNIQWLR,   +2y5 
BSEP 515.2956 602.3409 SLNIQWLR,   +2y4 
BCRP 573.2846 961.4408 LATTMTNHEK,   +2y8 
BCRP 573.2846 759.3454 LATTMTNHEK,   +2y6 
BCRP 573.2846 527.2572 LATTMTNHEK,   +2y4 
BCRP 478.5819 504.2453 LAEIYVNSSFYK,   +3y8+2 
BCRP 478.5819 316.1579 LAEIYVNSSFYK,   +3y5+2 
MATE1 514.7722 688.3988 GGPEATLEVR,   +2y6 
MATE1 514.7722 617.3617 GGPEATLEVR,   +2y5 
MATE1 514.7722 409.2243 GGPEATLEVR,   +2y7+2 
MATE1 641.1041 656.4454 GLLLLGVFLILLVGILVR,   +3y6 
MATE1 641.1041 557.3770 GLLLLGVFLILLVGILVR,   +3y5 
MATE1 641.1041 628.4287 GLLLLGVFLILLVGILVR,   +3y11+2 
MDR1 438.2327 717.3890 GTQLSGGQK,   +2y7 
MDR1 438.2327 589.3304 GTQLSGGQK,   +2y6 
MDR1 438.2327 476.2463 GTQLSGGQK,   +2y5 
MDR1 944.5180 819.4472 LSTIQNADLIVVFQNGR,   +2y7 
MDR1 944.5180 720.3787 LSTIQNADLIVVFQNGR,   +2y6 
MDR1 944.5180 474.2419 LSTIQNADLIVVFQNGR,   +2y4 
MDR3 824.4250 1288.7260 FVDTAGNFSFPVNFSLSLLNPGK,   +3y12 
MDR3 824.4250 969.5096 FVDTAGNFSFPVNFSLSLLNPGK,   +3y18+2 
MDR3 824.4250 766.9272 FVDTAGNFSFPVNFSLSLLNPGK,   +3y14+2 
MDR3 523.3037 857.5203 STTVQLIQR,   +2y7 
MDR3 523.3037 756.4726 STTVQLIQR,   +2y6 
MDR3 523.3037 329.2058 STTVQLIQR,   +2y5+2 
MRP2 777.0112 1330.6022 AMQFSEASFTWEHDSEATVR,   +3y11 




MRP2 777.0112 914.4326 AMQFSEASFTWEHDSEATVR,   +3y8 
MRP2 521.2536 747.3632 FFDTTPTGR,   +2y7 
MRP2 521.2536 632.3362 FFDTTPTGR,   +2y6 
MRP2 521.2536 430.2409 FFDTTPTGR,   +2y4 
Sterolin-1 532.7739 862.4451 TTLLDAMSGR,   +2y8 
Sterolin-1 532.7739 749.3610 TTLLDAMSGR,   +2y7 
Sterolin-1 532.7739 636.2770 TTLLDAMSGR,   +2y6 
Sterolin-1 588.3666 864.5050 IVVLTIHQPR,   +2y7 
Sterolin-1 588.3666 751.4209 IVVLTIHQPR,   +2y6 
Sterolin-1 588.3666 650.3733 IVVLTIHQPR,   +2y5 
Sterolin-2 588.3666 650.3733 LVLISLHQPR,   +2y5 
Sterolin-2 588.3666 482.2904 LVLISLHQPR,   +2y8+2 
Sterolin-2 588.3666 369.2063 LVLISLHQPR,   +2y6+2 
Sterolin-2 938.4416 813.3939 YSNPADFYVDLTSIDR,   +2y14+2 
Sterolin-2 938.4416 541.2798 YSNPADFYVDLTSIDR,   +2y9+2 
Sterolin-2 938.4416 410.2140 YSNPADFYVDLTSIDR,   +2y7+2 
OAT7 500.6011 1089.5357 ISIPLDSNMRPEK,   +3y9 
OAT7 500.6011 976.4517 ISIPLDSNMRPEK,   +3y8 
OAT7 500.6011 861.4247 ISIPLDSNMRPEK,   +3y7 
OAT7 523.3106 829.5393 DTLTLEILK,   +2y7 
OAT7 523.3106 716.4553 DTLTLEILK,   +2y6 
OAT7 523.3106 615.4076 DTLTLEILK,   +2y5 
OCT3 471.7538 559.3198 GPSAAALAER,   +2y5 
OCT3 471.7538 488.2827 GPSAAALAER,   +2y4 
OCT3 471.7538 375.1987 GPSAAALAER,   +2y3 
ENT1 488.9196 1079.5844 DAQASAAPAAPLPER,   +3y11 
ENT1 488.9196 850.4781 DAQASAAPAAPLPER,   +3y8 
ENT2 440.5528 818.4254 SSQAQAQELETK,   +3y7 
ENT2 440.5528 619.3297 SSQAQAQELETK,   +3y5 
ENT2 440.5528 490.2871 SSQAQAQELETK,   +3y4 
ENT2 858.3992 904.3795 SLTSYFLWPDEDSR,   +2y7 
ENT2 858.3992 621.2475 SLTSYFLWPDEDSR,   +2y5 
ENT2 858.3992 758.3412 SLTSYFLWPDEDSR,   +2y12+2 
NTCP 768.0472 1090.5891 MIYTAATTEETIPGALGNGTYK,   +3y11 
NTCP 768.0472 823.4308 MIYTAATTEETIPGALGNGTYK,   +3y8 
NTCP 768.0472 468.2453 MIYTAATTEETIPGALGNGTYK,   +3y4 
 
 
 
 
 
 
